<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐seizure medications for Lennox‐Gastaut syndrome - Brigo, F - 2021 | Cochrane Library</title> <meta content="Anti‐seizure medications for Lennox‐Gastaut syndrome - Brigo, F - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003277.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐seizure medications for Lennox‐Gastaut syndrome - Brigo, F - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003277.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003277.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐seizure medications for Lennox‐Gastaut syndrome" name="citation_title"/> <meta content="Francesco Brigo" name="citation_author"/> <meta content="Hospital of Merano (SABES-ASDAA)" name="citation_author_institution"/> <meta content="dr.francescobrigo@gmail.com" name="citation_author_email"/> <meta content="Katherine Jones" name="citation_author"/> <meta content="Christin Eltze" name="citation_author"/> <meta content="Sara Matricardi" name="citation_author"/> <meta content="Children’s Hospital “G. Salesi”, Ospedali Riuniti Ancona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD003277.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003277.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003277.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003277.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Age of Onset; Anticonvulsants [administration &amp; dosage, adverse effects]; Cannabidiol [administration &amp; dosage, adverse effects]; Cinnamates [administration &amp; dosage, adverse effects]; Clobazam [administration &amp; dosage]; Electroencephalography; Felbamate [administration &amp; dosage]; Lamotrigine [administration &amp; dosage]; Lennox Gastaut Syndrome [*drug therapy]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Topiramate [administration &amp; dosage]; Triazoles [administration &amp; dosage]; Wakefulness [physiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003277.pub4&amp;doi=10.1002/14651858.CD003277.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003277\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003277\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","pt","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003277.pub4",title:"Anti\\u2010seizure medications for Lennox\\u2010Gastaut syndrome",firstPublishedDate:"Apr 7, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003277.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003277.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003277.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003277.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003277.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003277.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003277.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003277.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003277.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003277.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5633 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003277.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0167"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-sec-0161"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/appendices#CD003277-sec-0172"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/table_n/CD003277StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/table_n/CD003277StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐seizure medications for Lennox‐Gastaut syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#CD003277-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Francesco Brigo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#CD003277-cr-0005">Katherine Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#CD003277-cr-0006">Christin Eltze</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information#CD003277-cr-0007">Sara Matricardi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information/en#CD003277-sec-0178">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003277.pub4">https://doi.org/10.1002/14651858.CD003277.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003277-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003277-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003277-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003277-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003277-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003277-abs-0005">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003277-abs-0001" lang="en"> <section id="CD003277-sec-0001"> <h3 class="title" id="CD003277-sec-0001">Background</h3> <p>Lennox‐Gastaut syndrome (LGS) is an age‐specific epilepsy syndrome characterised by multiple seizure types. LGS has a characteristic electroencephalogram, an onset before age eight years, and drug resistance. </p> <p>This is an updated version of the Cochrane Review published in 2013.</p> </section> <section id="CD003277-sec-0002"> <h3 class="title" id="CD003277-sec-0002">Objectives</h3> <p>To assess the efficacy and tolerability of anti‐seizure medications (ASMs) for LGS.</p> </section> <section id="CD003277-sec-0003"> <h3 class="title" id="CD003277-sec-0003">Search methods</h3> <p>We searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 28 February 2020) on 2 March 2020. CRS Web includes randomised controlled trials (RCTs) or quasi‐RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL); the Specialised Registers of Cochrane Review Groups, including Cochrane Epilepsy; PubMed; Embase; ClinicalTrials.gov; and the World Health Organization's International Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We contacted pharmaceutical companies and colleagues in the field to seek any unpublished or ongoing studies. </p> </section> <section id="CD003277-sec-0004"> <h3 class="title" id="CD003277-sec-0004">Selection criteria</h3> <p>We considered RCTs, including cross‐over trials, of ASMs for LGS in children and adults. We included studies of ASMs used as either monotherapy or as add‐on (adjunctive) therapy. We excluded studies comparing different doses of the same ASM. </p> </section> <section id="CD003277-sec-0005"> <h3 class="title" id="CD003277-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures, including independent, dual assessment for risk of bias, and applying the GRADE approach to rate the evidence certainty for outcomes. </p> </section> <section id="CD003277-sec-0006"> <h3 class="title" id="CD003277-sec-0006">Main results</h3> <p>We found no trials of ASM monotherapy. The review included 11 trials (1277 participants; approximately 11 weeks to 112 weeks follow‐up after randomisation) using add‐on ASMs for LGS in children, adolescents, and adults. </p> <p>Two studies compared add‐on cannabidiol (two doses) with add‐on placebo in children, adolescents, and adults. Insufficient information was provided for calculation of different response rate proportions in all seizures. We found high‐certainty evidence that 82 more people per 1000 (confidence interval (CI) 19 more to 350 more) had adverse events (AE) leading to study discontinuation with add‐on cannabidiol, compared to add‐on placebo (two studies; 396 participants; risk ratio (RR) 6.62, 95% CI 1.56 to 28.15). </p> <p>One study compared add‐on cinromide with add‐on placebo in children and adolescents only. We found very low‐certainty evidence that 35 more people per 1000 (CI 123 fewer to 434 more) had 50% or greater average reduction of overall seizures with add‐on cinromide compared to add‐on placebo (one study; 56 participants; RR 1.15, 95% CI 0.47 to 2.86). This study did not report participants with AE leading to study discontinuation. </p> <p>One study compared add‐on clobazam (three doses) with add‐on placebo. This study did not report overall seizure cessation or reduction. We found high‐certainty evidence that 106 more people per 1000 (CI 0 more to 538 more) had AE leading to study discontinuation with add‐on clobazam compared to add‐on placebo (one study; 238 participants; RR 4.12, 95% CI 1.01 to 16.87). </p> <p>One study compared add‐on felbamate with add‐on placebo. No cases of seizure cessation occurred in either regimen during the treatment phase (one study; 73 participants; low‐certainty evidence). There was low‐certainty evidence that 53 more people per 1000 (CI 19 fewer to 716 more) with add‐on felbamate were seizure‐free during an EEG recording at the end of the treatment phase, compared to add‐on placebo (RR 2.92, 95% CI 0.32 to 26.77). The study did not report overall seizure reduction. We found low‐certainty evidence that one fewer person per 1000 (CI 26 fewer to 388 more) with add‐on felbamate had AE leading to study discontinuation compared to add‐on placebo (one study, 73 participants; RR 0.97, 95% CI 0.06 to 14.97). </p> <p>Two studies compared add‐on lamotrigine with add‐on placebo. Neither study reported overall seizure cessation. We found high‐certainty evidence that 176 more people per 1000 (CI 30 more to 434 more) had ≥ 50% average seizure reduction with add‐on lamotrigine compared to add‐on placebo (one study; 167 participants; RR 2.12, 95% CI 1.19 to 3.76). We found low‐certainty evidence that 40 fewer people per 1000 (CI 68 fewer to 64 more) had AE leading to study‐discontinuation with add‐on lamotrigine compared to add‐on placebo (one study; 169 participants; RR 0.49, 95% CI 0.13 to 1.82). </p> <p>Two studies compared add‐on rufinamide with add‐on placebo. Neither study reported seizure cessation. We found high‐certainty evidence that 202 more people per 1000 (CI 34 to 567 more) had ≥ 50% average seizure reduction (one study; 138 participants; RR 2.84, 95% CI 1.31 to 6.18). We found low‐certainty evidence that 105 more people per 1000 (CI 17 fewer to 967 more) had AE leading to study discontinuation with add‐on rufinamide compared to add‐on placebo (one study; 59 participants; RR 4.14, 95% CI 0.49 to 34.86). One study compared add‐on rufinamide with another add‐on ASM. This study did not report overall seizure cessation or reduction. We found low‐certainty evidence that three fewer people per 1000 (CI 75 fewer to 715 more) had AE leading to study discontinuation with add‐on rufinamide compared to another add‐on ASM (one study; 37 participants; RR 0.96, 95% CI 0.10 to 9.57). </p> <p>One study compared add‐on topiramate with add‐on placebo. This study did not report overall seizure cessation. We found low‐certainty evidence for ≥ 75% average seizure reduction with add‐on topiramate (one study; 98 participants; Peto odds ratio (Peto OR) 8.22, 99% CI 0.60 to 112.62) and little or no difference to AE leading to study discontinuation compared to add‐on placebo; no participants experienced AE leading to study discontinuation (one study; 98 participants; low‐certainty evidence). </p> </section> <section id="CD003277-sec-0007"> <h3 class="title" id="CD003277-sec-0007">Authors' conclusions</h3> <p>RCTs of monotherapy and head‐to‐head comparison of add‐on ASMs are currently lacking. However, we found high‐certainty evidence for overall seizure reduction with add‐on lamotrigine and rufinamide, with low‐certainty evidence for AE leading to study discontinuation compared with add‐on placebo or another add‐on ASM. The evidence for other add‐on ASMs for overall seizure cessation or reduction was low to very low with high‐ to low‐certainty evidence for AE leading to study discontinuation. </p> <p>Future research should consider outcome reporting of overall seizure reduction (applying automated seizure detection devices), impact on development, cognition and behaviour; future research should also investigate age‐specific efficacy of ASMs and target underlying aetiologies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003277-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003277-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003277-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003277-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003277-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003277-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003277-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003277-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003277-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003277-abs-0002" lang="en"> <h3>Are anti‐seizure medications effective and safe treatments for Lennox‐Gastaut syndrome?</h3> <p><b>Why is this question important?</b> </p> <p>Lennox‐Gastaut syndrome (LGS) is a severe type of epilepsy that mainly affects children. The main symptom in LGS is frequent and multiple types of seizures. Seizures are caused by sudden and uncontrolled surges of abnormal electrical activity in the brain. The seizures are difficult to treat with anti‐seizure medications (ASMs). Many different ASMs are given to try and stop the seizures. Two or three ASMs are often given at the same time, which is known as polypharmacy. It is unclear which medications are most effective. Most people with LGS also have learning and behavioural difficulties. </p> <p><b>How did we identify and evaluate the evidence?</b> </p> <p>We searched the medical literature for randomised controlled trials (RCTs) analysing the effects of anti‐seizure medications (ASMs) for treating LGS. We included any RCT that compared ASMs, whether as monotherapy or add‐on (adjunctive) therapy, with placebo (pretend treatment), no treatment or another kind of treatment. We then compared the results of the RCTs we found, and summarised the evidence from all the studies. We rated our confidence in the 'certainty' of evidence, based on factors such as study methods and sizes, and the consistency of findings across studies. </p> <p><b>Study characteristics</b> </p> <p>This review included 11 trials (1277 participants, including children, adolescents and adults). The trials lasted between about 11 weeks and 112 weeks after randomisation. None of the included trials compared one ASM on its own with another treatment. Two trials compared add‐on cannabidiol regimens (cannabis‐based medicine) with add‐on placebo regimens (396 children, adolescents and adults ). One trial compared an add‐on cinromide regimen with an add‐on placebo regimen (56 children and adolescents only). One trial compared an add‐on clobazam regimen with an add‐on placebo regimen (238 participants). One trial compared an add‐on felbamate regimen with an add‐on placebo regimen (73 participants). Two trials compared add‐on lamotrigine regimens with add‐on placebo regimens (186 participants). Two trials compared add‐on rufinamide regimens with add‐on placebo regimens (197 participants). One trial compared an add‐on rufinamide regimen with another ASM regimen (37 participants). One trial compared an add‐on topiramate regimen with an add‐on placebo regimen (98 participants). </p> <p>Most of the evidence in this review related to people from middle‐ or high‐income countries and, where reported, participants of white ethnicity. </p> <p><b>Results and certainty of the evidence</b> </p> <p>We found high‐certainty evidence that add‐on lamotrigine increased the number of participants with at least 50% reduction in the average number of reported seizures. We also found low‐certainty evidence that add‐on lamotrigine may have reduced the number of participants with adverse events leading to study discontinuation when compared to add‐on placebo. </p> <p>We found high‐certainty evidence that add‐on rufinamide increased the number of participants with at least 50% reduction in the average number of reported seizures, when compared with add‐on placebo. We also found low‐certainty evidence that add‐on rufinamide may have little or no difference in effect, compared to add‐on placebo or another unspecified ASM, on reduction of the number of participants with adverse events leading to study discontinuation. </p> <p>Add‐on topiramate may have increased the number of participants with at least 75% reduction in the average number of reported seizures, and probably made little or no difference to the number of adverse events leading to study discontinuation, when compared to add‐on placebo (low‐certainty evidence). </p> <p>Add‐on felbamate (treatment phase) may have made little or no difference in terms of reported seizure freedom and adverse events leading to study discontinuation when compared to add‐on placebo (low‐certainty evidence). However, we found that when seizures were recorded in a research setting, add‐on felbamate may have increased seizure freedom compared to add‐on placebo (low‐certainty evidence). </p> <p>We remain uncertain whether other add‐on drug therapies, including cannabidiol, cinromide and clobazam, reduced all types of seizures because this outcome was not reported or had very low‐certainty evidence. We found high‐certainty evidence that add‐on cannabidiol and add‐on clobazam increased the number of participants with adverse events leading to study discontinuation, when compared to add‐on placebo. We did not find any evidence for adverse events leading to study discontinuation in the comparison of add‐on cinromide with add‐on placebo. </p> <p>The evidence is current to March 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003277-sec-0167" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003277-sec-0167"></div> <h3 class="title" id="CD003277-sec-0168">Implications for practice</h3> <section id="CD003277-sec-0168"> <p>There is currently a lack of randomised controlled trial (RCT) evidence on the optimal monotherapy for Lennox‐Gastaut syndrome (LGS). However, we found high‐certainty evidence for reduction in average reported seizures with add‐on lamotrigine and rufinamide, and low‐certainty evidence that these treatments may have reduced or made little or no difference to the number of participants with adverse events leading to study discontinuation, when compared with add‐on placebo or another add‐on ASM, respectively. We found very little information on the effects of treatment on development, cognition and behaviour, and incomplete reporting for overall seizure reduction and adverse events leading to study discontinuation across most RCTs of add‐on anti‐seizure medications (ASMs). </p> </section> <h3 class="title" id="CD003277-sec-0169">Implications for research</h3> <section id="CD003277-sec-0169"> <p>There is a need for high‐quality RCTs to establish the optimal ASM monotherapy for LGS and optimal add‐on treatment through head‐to‐head comparison of add‐on ASMs. We also think more research is necessary across ethnically and geographically diverse populations; outcome reporting needs to include overall seizure cessation and reduction (e.g. recorded under observation if reporting is too difficult), and the impact on developmental progress, cognition, and behaviour. We think future research will need to consider economic evaluation of the different drug treatments for LGS. We also think further studies could explore the efficacy of ASMs within different age groups and aetiologies of LGS. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003277-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003277-sec-0008"></div> <div class="table" id="CD003277-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries<br/><b>Intervention:</b> cannabidiol (10mg/kg and 20mg/kg) + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cannabidiol + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures follow up: after 14 weeks' treatment (titration and maintenance) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. No participants were free from drop seizures (one study; 225 participants) <a href="./references#CD003277-fig-0003" title="">Analysis 1.1</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 14 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants with ≥ 75% reduction in drop seizures: RR 3.51 (95% CI 1.24 to 9.92) in favour of the cannabidiol regimen (two studies; 396 participants) <a href="./references#CD003277-fig-0004" title="">Analysis 1.2</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 14 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants with ≥ 50% reduction in drop seizures: RR 2.12 (95% CI 1.48 to 3.03) in favour of the cannabidiol regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0005" title="">Analysis 1.3</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 19 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.62<br/>(1.56 to 28.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention in <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> involved two doses of cannabidiol (10 mg/kg and 20 mg/kg); 6 of the 7 adverse events leading to study discontinuation occurred in the higher dose group; intervention in <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a> also involved the higher dose of cannabidiol (20 mg/kg). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(19 to 350) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003277-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cinromide plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cinromide + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<sup>1</sup><br/><b>Setting:</b> USA<br/><b>Intervention:</b> cinromide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cinromide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 75% reduction in mean weekly seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 9.35<br/>(0.45 to 194.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cinromide + ASMs: 3/26 participants;</p> <p>placebo + ASMs: 0/30 participants.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% reduction in mean weekly seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/>(0.47 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/>(110 to 667) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with adverse events leading to study discontinuation</p> <p>follow‐up: after 18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>Peto</b> <b>OR:</b> Peto<b>o</b>dds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The evidence for this comparison included children and adolescents only. </p> <p><sup>2</sup>Downgraded twice for study limitations because there was a high risk of bias from incomplete data (study terminated prematurely). </p> <p><sup>3</sup>Downgraded twice for imprecision because the study was not powered to detect a between‐group difference in zero event outcomes. </p> <p><sup>4</sup>Downgraded twice for imprecision because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003277-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clobazam (low, medium and high doses) plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clobazam (low, medium and high doses) + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries and one middle‐income country<br/><b>Intervention:</b> clobazam (low, medium and high doses) + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clobazam + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants free from drop seizures: RR 4.10 (95% CI 1.00 to 16.83) in favour of the clobazam regimen (1 study; 217 participants) <a href="./references#CD003277-fig-0032" title="">Analysis 3.1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: 22 weeks (after baseline, titration, maintenance and tapering) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.12<br/>(1.01 to 16.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention in <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a> involved three doses of clobazam (low, medium, high) and study authors state that "A dosage related trend was observed for the overall incidence of [adverse events] leading to discontinuation." </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000<br/>(34 to 572) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003277-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Felbamate plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Felbamate + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> USA<br/><b>Intervention:</b> felbamate + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with felbamate + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) ‐<br/>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.92<br/>(0.32 to 26.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(9 to 744) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures<br/>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to a retrospective analysis "Approximately 50% of patients randomised to FBM obtained at least a 50% reduction in seizure frequency compared with about 15% receiving placebo." </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow up: after 14 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.06 to 14.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(2 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval;<b>FBM:</b> felbamate; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice for imprecision because the effect estimate has a very wide confidence interval. </p> <p><sup>2</sup>Downgraded twice for imprecision because the study was not powered to detect a between‐group difference in zero event outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003277-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lamotrigine plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre<br/><b>Intervention:</b> lamotrigine + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 16 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 16 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% median reduction in all seizures<br/>follow‐up: after 16 weeks' treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/>(1.19 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>167<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(187 to 591) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 20 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49<br/>(0.13 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>169<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(10 to 142) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003277-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Rufinamide plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rufinamide + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries and one middle‐income country<br/><b>Intervention:</b> rufinamide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with rufinamide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% reduction in all seizures<br/>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.84<br/>(1.31 to 6.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(143 to 676) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with adverse events leading to study discontinuation</p> <p>follow‐up: after 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>138 per 1000</p> <p>(16 to 1,000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.14 (0.49 to 34.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003277-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rufinamide plus ASMs compared to other ASM plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rufinamide + ASMs compared to other ASM + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries<br/><b>Intervention:</b> rufinamide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with rufinamide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with treatment‐emergent adverse events leading to study discontinuation<br/>follow‐up: after 112 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.10 to 9.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/>(8 to 798) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003277-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Topiramate plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topiramate + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, USA<br/><b>Intervention:</b> topiramate + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Topiramate+ ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 11 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 75% reduction in all seizures<br/>follow‐up: after 11 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 8.22<br/>(0.60 to 112.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate + ASMs: 4/48 participants;</p> <p>placebo + ASMs: 0/50 participants.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 11 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 11 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> <p><sup>2</sup>Downgraded twice because the study was not powered to detect a between‐group difference in zero event outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003277-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003277-sec-0009"></div> <section id="CD003277-sec-0010"> <h3 class="title" id="CD003277-sec-0010">Description of the condition</h3> <p>This is an updated version of the Cochrane Review published in 2013 (<a href="./references#CD003277-bbs2-0075" title="HancockEC , CrossJH . Treatment of Lennox‐Gastaut syndrome. Cochrane Database of Systematic Reviews2013, Issue 2. Art. No: CD003277. [DOI: 10.1002/14651858.CD003277.pub3]">Hancock 2013</a>). </p> <p>Lennox‐Gastaut Syndrome (LGS) is a severe chronic epilepsy syndrome with onset in early childhood (seizure onset between one and seven years of age, with a peak age of onset at three to five years) (<a href="./references#CD003277-bbs2-0051" title="International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia1989;30(4):389-99.">ILAE 1989</a>; <a href="./references#CD003277-bbs2-0052" title="International League Against Epilepsy. Lennox Gastaut syndrome. https://www.epilepsydiagnosis.org/syndrome/lgs-overview.html (accessed 7 December 2020).">ILAE 2020</a>). The disorder commonly persists, with drug‐resistant seizures throughout life (<a href="./references#CD003277-bbs2-0031" title="ArzimanoglouA , FrenchJ , BlumeWT , CrossJ , ErnstJP , FeuchtM , et al. Lennox Gastaut syndrome: a consensus approach on diagnosis, assessment, management and trial methodology. Lancet Neurology2009;8(1):82-93. [PMID: 19081517]">Arzimanoglou 2009</a>). </p> <p>People with LGS often have ongoing care needs into adulthood because of significant comorbidities, including cognitive, behavioural, and motor impairments. Along with the drug‐resistant seizures, associated severe behavioural and psychiatric disorders can be particularly challenging to manage clinically, as well as by the person living with LGS, their families and caregivers. In addition to the consequences of the underlying aetiology, LGS is regarded as a developmental and epileptic encephalopathy, a concept that refers to the adverse and disruptive impact of frequent epileptiform activity on cerebral activity, even in the absence of clinical seizures. </p> <p>LGS represents approximately 3% to 5% of all childhood onset epilepsies. In population‐based childhood epilepsy incidence cohorts, only up to 0.9% of patients are identified with LGS when epilepsy is diagnosed; other defining characteristics such as multiple seizure types and electroencephalogram (EEG) features evolve over time (<a href="./references#CD003277-bbs2-0035" title="BergAT , ShinnarS , LevySR , TestaFM . Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia1999;40(4):445-52. [PMID: 10219270]">Berg 1999</a>; <a href="./references#CD003277-bbs2-0036" title="BergAT , LevySR , TestaFM . Evolution and course of early life developmental encephalopathic epilepsies: focus on Lennox-Gastaut syndrome. Epilepsia2018;59(11):2096-105. [PMID: 30255934]">Berg 2018</a>; <a href="./references#CD003277-bbs2-0040" title="CallenbachPM , GeertsAT , ArtsWF , vanDonselaarCA , PetersAC , StroinkH , et al. Familial occurrence of epilepsy in children with newly diagnosed multiple seizures: Dutch Study of Epilepsy in Childhood. Epilepsia1998;39(3):331-6. [PMID: 9578054]">Callenbach 1998</a>; <a href="./references#CD003277-bbs2-0071" title="WirrellEC , GrossardtBR , Wong-KisielLC , NickelsKC . Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Research2011;95(1-2):110-8. [PMID: 21482075]">Wirrell 2011</a>). The prevalence of LGS was estimated at 26 per 100,000 in a regional US study (<a href="./references#CD003277-bbs2-0068" title="TrevathanE , MurphyCC , Yeargin-AllsoppM . Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia1997;38(12):1283-8. [PMID: 9578523]">Trevathan 1997</a>). This syndrome presents with multiple seizure types and in some people, follows initial presentation with infantile spasms. For three in ten people, LGS may evolve following the initial presentation in infancy with West syndrome (infantile spasms) or Ohtahara syndrome (<a href="./references#CD003277-bbs2-0043" title="CrossJH , AuvinS , FalipM , StrianoP , ArzimanoglouA . Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Frontiers in Neurology2017;8:505. [PMID: 29085326]">Cross 2017</a>). However, there are also cases of late‐onset LGS with seizure onset after the age of 10 years, in adolescence and adulthood (<a href="./references#CD003277-bbs2-0067" title="SmithKM , BrittonJW , CascinoGD . Late-onset Lennox-Gastaut syndrome: diagnostic evaluation and outcome. Neurology. Clinical Practice2018;8(5):397-402. [PMID: 30564493]">Smith 2018</a>). </p> <p>Underlying aetiologies, identified in 60% to 75% of patients with LGS, are diverse, and include developmental structural brain abnormalities, chromosomal derangements, monogenetic conditions, and less frequently, metabolic disorders and acquired brain insults (e.g. perinatal hypoxic‐ischaemic brain injuries, perinatal CNS infections) (<a href="./references#CD003277-bbs2-0032" title="Asadi-PooyaAA . Lennox-Gastaut syndrome: a comprehensive review. Neurological Sciences2018;39(3):403-14. [PMID: 29124439]">Asadi‐Pooya 2018</a>). The diagnosis of LGS in early childhood can be challenging due to the overlap in clinical presentation with other epileptic syndromes, especially epilepsy with myoclonic‐atonic seizures’ (<a href="./references#CD003277-bbs2-0043" title="CrossJH , AuvinS , FalipM , StrianoP , ArzimanoglouA . Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Frontiers in Neurology2017;8:505. [PMID: 29085326]">Cross 2017</a>; <a href="./references#CD003277-bbs2-0045" title="EschbachK , MossA , JoshiC , AngioneK , SmithG , DempseyA , et al. Diagnosis switching and outcomes in a cohort of patients with potential epilepsy with myoclonic-atonic seizures. Epilepsy Research2018;147:95-101. [PMID: 30286391]">Eschbach 2018</a>; <a href="./references#CD003277-bbs2-0054" title="KaminskaA , IckowiczA , PlouinP , BruMF , DellatolasG , DulacO . Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Research1999;36(1):15-29. [PMID: 10463847]">Kaminska 1999</a>). </p> <p>The occurrence of tonic seizures is mandatory for the diagnosis of LGS (<a href="./references#CD003277-bbs2-0052" title="International League Against Epilepsy. Lennox Gastaut syndrome. https://www.epilepsydiagnosis.org/syndrome/lgs-overview.html (accessed 7 December 2020).">ILAE 2020</a>). While atypical absence seizures are the second most characteristic seizure type in LGS, other observed seizure types also include generalised tonic‐clonic, atonic, myoclonic, myoclonic‐atonic, focal seizures, and epileptic spasms (<a href="./references#CD003277-bbs2-0042" title="CrespelA , GelisseP , MacorigG , NikanorovaM , FerlazzoE , GentonP . Lennox-Gastaut syndrome. In: Bureau M, GentonP , Delgado-EscuetaA , DravetC , GuerriniR , TassinariCA , et al, editors(s). Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th edition. Paris: John Libbey Eurotext, 2019. [ISBN: 978-2742015726]">Crespel 2019</a>). The EEG features that form part of the fully evolved electro‐clinical syndrome are slow spike‐wave discharges (&lt; 2.5 Hz) and generalised paroxysmal fast activity in slow wave sleep. Prolonged periods of obtundation or episodes of non‐convulsive status epilepticus are other common epilepsy manifestations interfering with cognitive and developmental function. These episodes and injuries sustained with seizures can have a negative impact on the quality of life as well as increase mortality risk (<a href="./references#CD003277-bbs2-0033" title="AutryAR , TrevathanE , Van Naarden BraunK , Yeargin-AllsoppM . Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. Journal of Child Neurology2010;25(4):441-7. [PMID: 20023065]">Autry 2010</a>; <a href="./references#CD003277-bbs2-0036" title="BergAT , LevySR , TestaFM . Evolution and course of early life developmental encephalopathic epilepsies: focus on Lennox-Gastaut syndrome. Epilepsia2018;59(11):2096-105. [PMID: 30255934]">Berg 2018</a>). </p> </section> <section id="CD003277-sec-0011"> <h3 class="title" id="CD003277-sec-0011">Description of the intervention</h3> <p>Eligible interventions included any type of anti‐seizure medication (ASM) as either monotherapy or add‐on (adjunctive) therapy. </p> </section> <section id="CD003277-sec-0012"> <h3 class="title" id="CD003277-sec-0012">How the intervention might work</h3> <p>ASMs provide symptomatic treatment with the intent to suppress seizure generation. To date, there is no evidence that ASMs can achieve disease modification and prevent the development of drug‐resistant seizures. Cellular targets for ASMs, in general, include voltage‐gated ion channels, receptors enhancing GABA inhibition or inhibit excitation mediated by glutamate receptors (<a href="./references#CD003277-bbs2-0064" title="RogawskiMA , LöscherW , RhoJM . Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harbor Perspectives in Medicine2016;6(5):a022780. [DOI: 10.1101/cshperspect.a022780] [PMID: 26801895]">Rogawski 2016</a>). The anti‐seizure effects of cannabidiol are proposed to be mediated by interaction with diverse molecular targets including G protein‐coupled receptor‐55 (GPR55‐antagonist), transient receptor potential vanilloid 1 (TRPV1‐ activation) channels and adenosine <sub>2A2</sub> receptors (<a href="./references#CD003277-bbs2-0030" title="AlvesP , AmaralC , TeixeiraN , Correia-da-SilvaG . Cannabis sativa: much more beyond Δ 9-tetrahydrocannabinol. Pharmacological Research2020;157:104822. [DOI: 10.1016/j.phrs.2020.104822] [PMID: 32335286]">Alves 2020</a>, <a href="./references#CD003277-bbs2-0057" title="LattanziS , TrinkaE , StrianoP , ZaccaraG , Del GiovaneC , Nardone R et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia2020;61(6):1090–8.">Lattanzi 2020</a>). Cinromide (3 brono‐N‐ethylcinnamide), an experimental agent, showed its anti‐seizure effect in animal models, through a mechanism of action that is not well understood (<a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). Felbamate (FBM) inhibits glycine‐enhanced N‐methyl‐D‐aspartate (NMDA)‐induced intracellular calcium currents, and at high concentrations, potentiates GABA responses and inhibits excitatory NMDA responses (<a href="./references#CD003277-bbs2-0066" title="ShorvonSD . Handbook of Epilepsy Treatment. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Clobazam enhances the inhibitory effects of GABA, binding to benzodiazepine receptors at the GABA<sub>A</sub> ligand‐gated chloride channel complex and boosting chloride conductance through GABA‐regulated channels (<a href="./references#CD003277-bbs2-0069" title="TrinkaE , BrigoF . Benzodiazepines used in the treatment of epilepsy. In: Treatment of epilepsies. 4th edition. Oxford: Blackwell Publishing, 2015.">Trinka 2015</a>, <a href="./references#CD003277-bbs2-0038" title="BrigoF , LattanziS . Anticonvulsant agents: benzodiazepines (clobazam, clonazepam, diazepam, lorazepam, midazolam). In: RiedererP , LauxG , NagatsuT , LeW , RiedererC , editors(s). NeuroPsychopharmacotherapy. Springer International Publishing, 2021. [ISBN: 978-3-030-62060-8]">Brigo 2021</a>). Lamotrigine acts as a use‐dependent blocker of voltage‐sensitive sodium channels, interacts with the open‐channel conformation of voltage‐sensitive sodium channels, interacts at a specific site of the alpha pore‐forming subunit of voltage‐sensitive sodium channels, and inhibits the release of glutamate (<a href="./references#CD003277-bbs2-0066" title="ShorvonSD . Handbook of Epilepsy Treatment. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Rufinamide acts as a blocker of voltage‐sensitive sodium channels and prevents sodium channels from returning to an activated state, thereby preventing the generation of sustained bursts of high‐frequency action potentials (<a href="./references#CD003277-bbs2-0066" title="ShorvonSD . Handbook of Epilepsy Treatment. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Topiramate has multiple mechanisms of action: it enhances GABA‐mediated inhibition, inhibits voltage‐dependent sodium channels, enhances potassium channel conduction; it also inhibits L‐type high voltage‐activated calcium channels, decreases glutamate‐mediated excitatory neurotransmission, and can inhibit carbonic anhydrase (<a href="./references#CD003277-bbs2-0066" title="ShorvonSD . Handbook of Epilepsy Treatment. Wiley-Blackwell, 2010.">Shorvon 2010</a>). </p> </section> <section id="CD003277-sec-0013"> <h3 class="title" id="CD003277-sec-0013">Why it is important to do this review</h3> <p>LGS is complex and one of the most medically refractory epilepsy syndromes. It impacts on individuals' learning, development and mental well‐being, as well as on the psychosocial and socio‐economic situation of families and caregivers. Furthermore, there is evidence to suggest that healthcare and medical treatment costs are higher for people with LGS compared to other types of epilepsy (<a href="./references#CD003277-bbs2-0062" title="Piña-GarzaJE , MontourisGD , VekemanF , ChengWY , TuttleE , Giguere-DuvalP , et al. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome. Epilepsy &amp; Behavior2017;73:46-50. [PMID: 28609734]">Pina‐Garza 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003277-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003277-sec-0014"></div> <p>To assess the efficacy and tolerability of anti‐seizure medications (ASMs) for LGS.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003277-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003277-sec-0015"></div> <section id="CD003277-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003277-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs), including cross‐over trials, of ASMs for LGS. </p> </section> <section id="CD003277-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included children and adults with a diagnosis of LGS. We did not apply age restrictions. As an electrochemical syndrome associated with specific types of epileptic seizures and a characteristic EEG pattern, the diagnosis of LGS was based on clinical criteria. These diagnostic criteria included but were not limited to those provided by the International League Against Epilepsy (<a href="./references#CD003277-bbs2-0051" title="International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia1989;30(4):389-99.">ILAE 1989</a>). </p> </section> <section id="CD003277-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any trial that compared ASMs (monotherapy or add‐on therapy) with placebo, no therapy or another therapy. We excluded trials evaluating ketogenic diet, vagus nerve stimulation or other non‐pharmaceutical treatments (including homeopathy or acupuncture) unless they were provided as a co‐intervention with ASMs. In this review update, we also excluded studies comparing different doses of the same drug, which is different to the previous version of this review, although dose comparisons were not pre‐specified in the methods of the review protocol. </p> </section> <section id="CD003277-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>If a study reported usable continuous and dichotomous data for quantitative reduction in seizures or other outcomes, we would have reported the dichotomous data as number of participants with a quantitative reduction in the outcome. We included outcome measures reported at any time point. If a study reported multiple time points, we planned to report and meta‐analyse the outcome at the longest follow‐up. However, we found that outcomes reported phases of dose adjustment before and, or after dose maintenance; we retrospectively agreed to prioritise the reporting of results for the treatment period as described in studies. </p> <section id="CD003277-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003277-list-0001"> <li> <p>Cessation of all seizures (defined as total cessation of all seizure types within the trial period) </p> </li> <li> <p>Quantitative reduction of all seizure types (measured as the number of all seizures occurring before treatment was commenced compared with the total number of seizures occurring at the end of the trial period) </p> </li> <li> <p>Adverse events leading to study discontinuation</p> </li> </ul> </p> </section> <section id="CD003277-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003277-list-0002"> <li> <p>Quantitative reduction in the following types of seizures (measured as the number of seizures occurring before treatment was commenced compared with the number occurring at the end of the trial period): absence seizures; tonic seizures; atonic seizures; drop seizures (defined as any seizure type resulting in postural loss); myoclonic seizures; tonic‐clonic seizures; and focal onset seizures </p> </li> <li> <p>Death (i.e. alive/deceased)</p> </li> <li> <p>Any adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD003277-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003277-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Searches were run for the original review in March 2003. Subsequent searches were run in February 2009, March 2011, April 2012, October 2012, July 2014, October 2016, and September 2018. For the latest update, we searched the following databases on 2 March 2020. There were no language restrictions. </p> <p> <ol id="CD003277-list-0003"> <li> <p>Cochrane Register of Studies (CRS Web), using the search strategy shown in <a href="./appendices#CD003277-sec-0173">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid), 1946 to 28 February 2020, using the search strategy shown in <a href="./appendices#CD003277-sec-0174">Appendix 2</a>. </p> </li> </ol> </p> <p>CRS Web includes RCTs or quasi‐RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL); the Specialised Registers of Cochrane Review Groups, including Cochrane Epilepsy; PubMed; Embase; ClinicalTrials.gov; and the World Health Organization's International Clinical Trials Registry Platform (ICTRP). </p> </section> <section id="CD003277-sec-0025"> <h4 class="title">Searching other resources</h4> <p>One review author (FB) contacted pharmaceutical companies (Eisai, GW Pharmaceuticals, and UCB Pharma) and colleagues in the field on 25 November 2020 in an effort to identify unpublished data. </p> </section> </section> <section id="CD003277-sec-0026"> <h3 class="title" id="CD003277-sec-0026">Data collection and analysis</h3> <p>At least two review authors (from among KJ, FB, CE, and SM) extracted data and resolved any discrepancies by discussion. </p> <section id="CD003277-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KJ and FB) examined records identified by the search strategy for studies eligible for inclusion. The review authors independently confirmed that studies were RCTs of drug treatment for LGS. </p> </section> <section id="CD003277-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (from among KJ, FB, CE, and SM) independently performed data extraction using a specially designed data extraction form. FB and KJ checked and entered data into the Cochrane authoring and statistical software, Review Manager 5 (<a href="./references#CD003277-bbs2-0063" title="Review Manager 5 (RevMan 5). Version 5.4.1. Cochrane, 2020.">Review Manager 2020</a>); at least one other review author (CE or SM) checked the data entry. </p> <p>For each trial, we sought the following information<i>.</i> </p> <section id="CD003277-sec-0029"> <h5 class="title">Participants</h5> <p> <ul id="CD003277-list-0004"> <li> <p>Inclusion criteria</p> </li> <li> <p>Exclusion criteria</p> </li> <li> <p>Total number randomised</p> </li> <li> <p>Baseline imbalances</p> </li> <li> <p>Withdrawals and exclusions</p> </li> <li> <p>Age at onset</p> </li> <li> <p>Age at diagnosis</p> </li> <li> <p>Age at start of treatment</p> </li> <li> <p>Sex</p> </li> <li> <p>Race/ethnicity</p> </li> <li> <p>Type of seizures</p> </li> <li> <p>Seizure frequency during the baseline period</p> </li> <li> <p>Number of background drugs</p> </li> <li> <p>Co‐morbidities</p> </li> </ul> </p> </section> <section id="CD003277-sec-0030"> <h5 class="title">Interventions</h5> <p> <ul id="CD003277-list-0005"> <li> <p>Type of intervention (description, including dose, frequency and route of administration)</p> </li> <li> <p>Number of participants randomised to each intervention</p> </li> <li> <p>Duration of baseline period</p> </li> <li> <p>Duration of treatment period</p> </li> <li> <p>Co‐interventions (if any)</p> </li> <li> <p>Compliance</p> </li> </ul> </p> </section> <section id="CD003277-sec-0031"> <h5 class="title">Outcome measures</h5> <p>For each outcome reported in the included studies we extracted the following data:</p> <p> <ul id="CD003277-list-0006"> <li> <p>Outcome name and definition</p> </li> <li> <p>Time point when each outcome was measured</p> </li> <li> <p>Time point when each outcome was reported</p> </li> <li> <p>Validation of the outcome (yes/no/unclear)</p> </li> <li> <p>Imputation of missing data (e.g. assumptions made for intention‐to‐treat (ITT) analysis)</p> </li> <li> <p>Assumed risk estimate (e.g. baseline or population risk noted in the <a href="#CD003277-sec-0009">Background</a>) </p> </li> <li> <p>Statistical power (e.g. power and sample size calculation, level of power achieved)</p> </li> </ul> </p> </section> </section> <section id="CD003277-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>At least two review authors (from among KJ, CE, and FB) independently assessed risk of bias for each of the included trials using the Cochrane 'Risk of bias' tool (<a href="./references#CD003277-bbs2-0049" title="Higgins JPT , Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We assessed risk of bias based on sequence generation, concealment of allocation, methods of blinding, incomplete outcome data, selective reporting, and other types of bias. For each of these categories, the review authors judged the domain to be at 'low', 'high', or 'unclear' risk of bias. We resolved any disagreements by discussion. </p> </section> <section id="CD003277-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data with a risk ratio (RR) and a 95% confidence interval (CI) or using the Peto odds ratio (Peto OR) and a 99% CI if there were less than 1% events. We analysed continuous data using the mean difference (MD) with a 95% CI where we found data provided as means and standard deviations (SDs). </p> </section> <section id="CD003277-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>For any unit of analysis issues, we planned to deal with them using the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003277-bbs2-0050" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>). We planned to analyse randomised cross‐over studies in meta‐analyses, using the results from paired analyses of the first period only to account for carry‐over effect with sequential intervention (<a href="./references#CD003277-bbs2-0050" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>). </p> <p>For studies in which different doses of the same drug were reported separately, we combined these data into a single treatment group to avoid a duplicative error with multiple‐armed trials. </p> </section> <section id="CD003277-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>For this review update, one review author (FB) attempted to contact the study authors of <a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a> to obtain missing outcome data. </p> </section> <section id="CD003277-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by visually inspecting forest plots, and by using the Chi² test and I² statistic as follows: 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% indicates considerable heterogeneity (<a href="./references#CD003277-bbs2-0044" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> </section> <section id="CD003277-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We would have used a funnel plot to explore small‐study biases in an outcome if data from sufficient studies (10 or more) had been pooled in a single meta‐analysis. </p> </section> <section id="CD003277-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model on the basis that drug trials assessed different but related intervention effects. </p> </section> <section id="CD003277-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We found insufficient evidence to perform subgroup analysis for dosage, timing, and length of treatment. </p> </section> <section id="CD003277-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>No sensitivity analyses were pre‐specified or undertaken.</p> </section> <section id="CD003277-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For this review update, we created 'Summary of findings' tables and used the GRADE approach to evaluate the certainty of the evidence (<a href="./references#CD003277-bbs2-0065" title="SchünemannHJ , VistGE , HigginsJPT , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). </p> <p>We included the following outcomes:</p> <p> <ol id="CD003277-list-0007"> <li> <p>Number of participants free from all seizures.</p> </li> <li> <p>Number of participants with ≥ 75% reduction in all seizures.</p> </li> <li> <p>Number of participants with ≥ 50% reduction in all seizures.</p> </li> <li> <p>Number of participants with adverse events leading to study discontinuation.</p> </li> </ol> </p> <p>Two review authors (from among KJ, FB, and CE) used the GRADE approach to judge the certainty of evidence for outcomes based on five criteria (risk of bias, inconsistency, indirectness, imprecision, and publication bias) (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013028.pub2/references#CD013028-bbs2-0027" target="_blank">Schunemann 2011</a>). If we had serious concerns regarding one of the five criteria, we downgraded the evidence from 'high quality' by one level; if we had very serious concerns, we downgraded the evidence by two levels. We resolved any discrepancies through discussion and reported our rationale for downgrading evidence in the 'Summary of findings' table footnotes. </p> <p>We used GRADEpro GDT software (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013028.pub2/references#CD013028-bbs2-0012" target="_blank">GRADEpro GDT 2015</a>) to record our judgements and to create the 'Summary of findings' tables for each comparison included in the review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003277-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003277-sec-0042"></div> <section id="CD003277-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD003277-sec-0044"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD003277-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003277-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003277-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified 40 studies, of which 11 met our inclusion criteria (1277 randomised participants). Four studies were published since the previous version of this review; see <a href="./references#CD003277-sec-0184" title="">Characteristics of included studies</a>. We excluded eight studies in total. We excluded two studies from the current review because they compared different doses of the same ASM (<a href="./references#CD003277-bbs2-0013" title="ConryJA , NgYT , PaolicchiJM , KernitskyL , MitchellWG , RitterFJ , et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia2009;50(5):1158-66. [PMID: 19170737]">Conry 2009</a>; <a href="./references#CD003277-bbs2-0014" title="InanagaK , KumashiroH , FukyamaY , OhtaharaS , ShirouzuM . Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia1989;30(4):438-45. [PMID: 2502385]">Inanaga 1989</a>), and three other studies were judged not to be RCTs (<a href="./references#CD003277-bbs2-0015" title="OletskyH , KelleyK , StertzB , Reeves-TyerP , FlaminiR , MalowB , et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):155, Abstract no: 6.13. ">Oletsky 1996</a>; <a href="./references#CD003277-bbs2-0016" title="PerryMS . Don't fear the reefer - evidence mounts for plant-based cannabidiol as treatment for epilepsy. Epilepsy Currents2019;19(2):93-5. [DOI: 10.1177/1535759719835671] [PMID: 30955420]">Perry 2019</a>; <a href="./references#CD003277-bbs2-0019" title="VigevanoF , CilioMR , AntoniniL . Clinical experience with Felbamate in paediatric age. In: Bollettino - Lega Italiana Contro L'Epilessia. Vol. 86-87. 1994:63-6. [DOI: 10.1016/s0920-1211(01)00290-x]">Vigevano 1994</a>). We also excluded three studies that were excluded in a previous version of this review because the outcome data were not reported in a usable way (<a href="./references#CD003277-bbs2-0012" title="BattagliaA , FerrariAR , GuerriniR . Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy. Brain and Development1991;13(4):217-22. [PMID: 1957968]">Battaglia 1991</a>; <a href="./references#CD003277-bbs2-0017" title="VajdaFJ , BladinPF , ParsonsBJ . Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clinical and Experimental Neurology1985;21:177-82. [PMID: 3843217]">Vajda 1985</a> ; <a href="./references#CD003277-bbs2-0018" title="VassellaF , RudebergA , Da SilvaV , PavlincovaE . Double-blind study on the anticonvulsive effect of phenobarbital and valproate in the Lennox syndrome [Doppletblind-Untersuchung uber die antikonvulsive Wirkung von Phenobarbital und Valproat beim Lennox-Syndrom]. Schweizerische Medizinische Wochenschrift1978;108(19):713-6. [PMID: 347569]">Vassella 1978</a>); see <a href="./references#CD003277-sec-0185" title="">Characteristics of excluded studies</a>. </p> <p>We identified eight ongoing studies from ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (<a href="./references#CD003277-bbs2-0021" title="CTRI/2010/091/001449. A comparative, randomized, open label, multicentric, prospective clinical study to evaluate the efficacy, safety and tolerability of rufinamide tablet vs. lamotrigine (adjunctive therapy) in the treatment of seizures associated with Lennox-Gastaut syndrome. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=22372011. ">CTRI/2010/091/001449</a>; <a href="./references#CD003277-bbs2-0022" title="NCT00004776. Phase III randomized, double-blind, placebo-controlled study of oral topiramate for Lennox-Gastaut syndrome. http://ClinicalTrials.gov/show/NCT000047761993. ">NCT00004776</a>; <a href="./references#CD003277-bbs2-0023" title="NCT01370486. Melatonin versus placebo in the Lennox-Gastaut syndrome: neurophysiological and neuropsychological effects. http://ClinicalTrials.gov/show/NCT013704862011. ">NCT01370486</a>; <a href="./references#CD003277-bbs2-0024" title="NCT02318537. Cannabidiol oral solution as an adjunctive therapy for treatment of subjects with inadequately controlled Lennox-Gastaut syndrome. https://ClinicalTrials.gov/show/NCT023185372016. ">NCT02318537</a>; <a href="./references#CD003277-bbs2-0025" title="NCT03355209. A study to investigate the efficacy and safety of ZX008 (fenfluramine hydrochloride) as an adjunctive therapy in children and adults with Lennox-Gastaut syndrome. https://clinicaltrials.gov/show/NCT03355209 (first received November 28, 2017). ">NCT03355209</a>; <a href="./references#CD003277-bbs2-0026" title="NCT03650452. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of TAK-935 (OV935) as an adjunctive therapy in pediatric patients with developmental and/or epileptic encephalopathies. https://ClinicalTrials.gov/show/NCT036504522018. ">NCT03650452</a>; <a href="./references#CD003277-bbs2-0027" title="NCT03808935. Cannabis extract in refractory epilepsy study. https://clinicaltrials.gov/show/NCT038089352019. ">NCT03808935</a>; <a href="./references#CD003277-bbs2-0028" title="WechslerRT , PopliG , DimosJ , FerreiraJ , BibbianiF , LaurenzaA , et al. Design and methods of study 338: a multicenter, double-blind, randomized, placebo-controlled trial of perampanel as adjunctive treatment in subjects &gt;=2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndrome. Epilepsia2017;58(Suppl 5):S157-8, Abstract no: p0891. [DOI: 10.1111/epi.13944]WechslerRT , PopliG , DimosJ , FerreiraJ , BibbianiF , LaurenzaA , et al. Design and methods of study 338: a multicentre, double-blind, randomised, placebo-controlled trial of perampanel as adjunctive treatment in patients &gt;=2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndrome. Developmental Medicine and Child Neurology2017;59(Suppl 4):121-2, Abstract no: 207. [DOI: 10.1111/dmcn.13623]">Wechsler 2017</a>); see <a href="./references#CD003277-sec-0187" title="">Characteristics of ongoing studies</a>. Of these eight trials, one trial of adjunctive rufinamide versus lamotrigine was terminated, and another trial of adjunctive cannabidiol versus placebo had its sponsorship withdrawn. Other adjunctive drug therapies under investigation included topiramate, melatonin, fenfluramine hydrochloride and TAK‐935 versus placebo. </p> <p>On 25 November 2020, one review author (FB) contacted pharmaceutical companies (Eisai, GW Pharmaceuticals, and UCB Pharma), and colleagues in the field to obtain information on any additional unpublished data. They identified no unpublished data relating to this review. On 4 December 2020, one review author (FB) also contacted the principal investigators of <a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a> to obtain information on missing data, and the principal investigators of <a href="./references#CD003277-bbs2-0023" title="NCT01370486. Melatonin versus placebo in the Lennox-Gastaut syndrome: neurophysiological and neuropsychological effects. http://ClinicalTrials.gov/show/NCT013704862011. ">NCT01370486</a> to obtain information on study completion. We received no response by the time of review completion. </p> <p>Despite its completion, we listed <a href="./references#CD003277-bbs2-0020" title="OhtaharaS , LinumaK , FujiwaraT , YamatogiY . Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy. Journal of the Japan Epilepsy Society2008;25(4):425-40. [DOI: 10.3805/jjes.25.425]">Ohtahara 2008</a> in <a href="./references#CD003277-bbs1-0003" title="">Studies awaiting classification</a> because we were unable to obtain a translation from the Japanese language into English. </p> </section> <section id="CD003277-sec-0045"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD003277-sec-0184" title="">Characteristics of included studies</a>. </p> <p>Two studies published protocols that we considered as part of the evidence synthesis (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). Of the 11 included studies, 10 were randomised and double‐blinded, placebo‐controlled trials (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>; <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>; <a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>; <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>; <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>; <a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>) and one was a randomised and double‐blinded, cross‐over, placebo‐controlled trial (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>). </p> <p>Two studies involved children and adolescents only, with ages ranging from one year to 18 years, (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>) and eight studies involved children, adolescents and adults, with ages ranging from over one year to 55 years (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>; <a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>; <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>; <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>; <a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). Another study of children, adolescents and young adults with refractory generalised epilepsy included a subgroup of participants with LGS who were all aged under 18 years (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>). </p> <p>In ten studies, diagnosis of LGS was reported according to clinical and EEG criteria or the classification of the International League Against Epilepsy (<a href="./references#CD003277-bbs2-0051" title="International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia1989;30(4):389-99.">ILAE 1989</a>); (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>; <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>; <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>; <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>; <a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). For one other study, the diagnosis was agreed by an international expert panel of child neurologists (<a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>). There was limited reporting of co‐morbidities in the study population but as many as 40% of participants from one study were reported to have underlying causes, such as tuberous sclerosis and cerebral palsy, cerebral dysgenesis, encephalitis and bacterial meningitis (<a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>). </p> <p>The drug treatment regimens of the included RCTs were as follows: cannabidiol and ASMs (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>); cinromide and ASMs (<a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>); clobazam and ASMs (<a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>); felbamate and ASMs (<a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>); lamotrigine and ASMs (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>); rufinamide and ASMs (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>; <a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>, and <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>); and topiramate and ASMs (<a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>). Aside from ASMs, the two most recent studies of add‐on cannabidiol reported non‐pharmacological co‐interventions including vagus nerve stimulation and ketogenic diet in a subset of participants (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). All studies included a pre‐randomisation, baseline period of four to eight weeks. The follow‐up after randomisation ranged from approximately 11 weeks to 112 weeks, including variable duration of titration and maintenance periods, with or without tapering, and safety follow‐up. </p> <p>In three studies, the primary outcome for treatment efficacy was overall seizure reduction, which was the main focus of the current review (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). Two studies included primary efficacy outcomes for overall seizure reduction and reduction in drop attacks or tonic‐atonic seizures (<a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>; <a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>). Four later studies had a primary efficacy outcome that focused on drop seizure or tonic‐atonic seizure reduction (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>; <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). The primary efficacy outcome was major motor seizures in one study (<a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>) and behavioural outcomes in another study (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>). </p> <section id="CD003277-sec-0046"> <h5 class="title">Arzimanoglou 2019</h5> <p><a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a> was conducted in 19 centres across Canada, France, Greece, Italy, Poland, and the United States. It involved 37 randomised children (aged one year to less than four years) with inadequately controlled LGS. The participants had LGS with seizures uncontrolled by a fixed dose of one to three concomitant ASMs for a minimum of four weeks before randomisation. The study included an eight‐week pre‐randomisation phase (screening period and baseline visit), followed by a 106‐week randomised phase (including titration and maintenance). Participants were randomised to receive add‐on rufinamide (target maintenance dose: 45 mg/kg/day in two divided doses, given as oral suspension) or any other ASM chosen by the investigator and added to the existing regimen of one to three ASMs. Baseline characteristics were similar in the trial groups although the 'Any other ASM' group had a higher proportion of males. The categories for ethnicity (Hispanic/Latino; non‐Hispanic/Latino) differed from those reported in the 6‐month dataset (White; Black or African‐American). Collectively, the baseline characteristics indicated mostly non‐Hispanic participants (more than 75%) and a majority of white participants (more than 70%) in the study. </p> </section> <section id="CD003277-sec-0047"> <h5 class="title">Devinsky 2018</h5> <p><a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> was conducted at 30 participating centres (20 in the United States, 5 in Spain, 3 in the United Kingdom, and 2 in France). It involved 225 randomised children and adults (aged 2 to 55 years). They took between one and four ASMs and had at least two drop seizures each week during the baseline period. Participants were randomised to receive add‐on cannabidiol at a dose of either 20 mg/kg/day or 10 mg/kg/day or matching add‐on placebo. The trial included a 4‐week baseline period, a 14‐week treatment period (2 weeks of dose escalation, followed by a maintenance phase of 12 weeks), a tapering period of up to 10 days, and a 4‐week safety follow‐up period after discontinuation of cannabidiol or placebo. Baseline characteristics were similar in the trial groups although a slightly higher proportion of the placebo group also received vagus nerve stimulation as a concomitant intervention (28%) as compared with the 10 and 20mg cannabidiol groups (21% each). The majority of study participants were of white ethnicity (more than 88%). </p> </section> <section id="CD003277-sec-0048"> <h5 class="title">Eriksson 1998</h5> <p><a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a> was conducted in Finland. The study initially involved 30 children (aged over two years), adolescents and two young adults with refractory generalised epilepsy. Twenty of the participants in the open phase had LGS, and all were aged under 18 years. Diagnostic criteria for LGS were based on the classification of the International League Against Epilepsy (<a href="./references#CD003277-bbs2-0051" title="International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia1989;30(4):389-99.">ILAE 1989</a>). All included participants experienced more than two seizures per month at baseline. The trial consisted of six phases. There was first an eight‐week baseline phase during which each child was observed on pre‐study medication, followed by an open phase, during which an attempt was made to find the optimal lamotrigine dose for each child. At the end of the open phase, children had been categorised as responders if they showed any improvement (in alertness, behaviour, motor skills, or seizures). The 'responders' (17/27 (13 with LGS); three excluded because of incomplete seizure diaries) were subsequently entered in a double‐blind phase of 12‐week periods during which, for each child, add‐on lamotrigine and placebo tablets were administered in random order. The treatment periods were separated by a three‐week washout phase. This study did not report participants' ethnicity and other characteristics for baseline comparison of treatment groups. </p> </section> <section id="CD003277-sec-0049"> <h5 class="title">Felbamate Study Group 1993</h5> <p><a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a> involved 73 randomised children and adults (aged 4 years to 36 years) and was conducted in the USA. Included participants had a history of multiple types of seizures and a minimum of 90 atonic seizures or atypical absence seizures per month during an eight‐week pre‐study phase; they took no more than two ASMs at baseline. The trial consisted of a 28‐day baseline period followed by a 14‐day titration phase and a 56‐day maintenance period. The initial dose of add‐on felbamate was 15 mg/kg/day, increased to 30 mg/kg after seven days and to either 14 mg/kg/day or 3600 mg/day (whichever was lower) after 14 days. Baseline characteristics were similar in the trial groups. The study largely involved people of white ethnicity (more than 89%). </p> </section> <section id="CD003277-sec-0050"> <h5 class="title">Glauser 2008</h5> <p><a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a> was conducted at 36 sites in nine countries (Belgium, Brazil, Germany, Hungary, Italy, Norway, Poland, Spain, and the United States). It involved 138 randomised children and adults (aged four years to 37 years). Study participants had a history of multiple seizure types, including atypical absence seizures and drop attacks, and a minimum of 90 seizures in the month prior to trial entry. At baseline, included participants took a fixed‐dose regimen of one to three concomitant ASMs. The trial consisted of a 28‐day baseline period at the end of which, patients continuing to meet the study criteria entered an 84‐day double‐blind treatment phase of either add‐on rufinamide or add‐on placebo. This phase consisted of a 14‐day titration period followed by a 70‐day maintenance period. Doses were titrated according to a recommended schedule based on body weight, up to a maximum dose of 45 mg/kg/day. </p> <p>Baseline characteristics of the two treatment groups were similar, including mostly male participants and with comparable usage of concomitant ASMs. However, a higher proportion of the add‐on placebo group was under 12 years of age, and a higher proportion of the add‐on rufinamide group was over 17 years of age. Both groups largely involved participants of white ethnicity. </p> </section> <section id="CD003277-sec-0051"> <h5 class="title">Group for the Evaluation of Cinromide 1989</h5> <p><a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a> involved 56 randomised children and adolescents (aged two years to 18 years) and was conducted in the USA. Included participants had seizures for at least six months prior to study entry. At baseline, no individual was receiving more than three marketed antiepileptic drugs and none had previous exposure to cinromide. The trial consisted of a six‐week baseline period, following which participants were randomised to receive either add‐on cinromide or add‐on placebo for a period of 18 weeks. Study medication was initiated at 20 to 40 mg/kg/day, divided into four equal doses. Further increases (to a total daily maximum of 83 to 109 mg/kg) were prescribed at weekly visits if each prior dose was tolerated and seizures continued. Baseline characteristics were comparable between groups, with the majority of study participants being of white ethnicity (more than 92%). </p> </section> <section id="CD003277-sec-0052"> <h5 class="title">Motte 1997</h5> <p><a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a> was conducted at 43 unspecified sites. The study involved 169 randomised children and young adults (aged three years to 25 years). Included participants experienced more than one type of predominantly generalised seizure for at least one year, and they had seizures at least every other day. They took up to three ASMs at baseline. The trial consisted of a four‐week baseline period during which all recipients received add‐on placebo. Participants were then randomised to receive either add‐on lamotrigine or add‐on placebo for a 16‐week treatment period. Participants were assigned to one of four dosing regimens according to concomitant valproate use and body weight based on paediatric dosing recommendations at that time. The characteristics of the two groups were similar at baseline although the lamotrigine group had a higher proportion of male participants. Both groups largely involved participants of white ethnicity (more than 90%). </p> </section> <section id="CD003277-sec-0053"> <h5 class="title">Ng 2011</h5> <p><a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a> was conducted at 51 sites in the United States, India, Europe, and Australia. It involved 238 randomised children and adults (aged 2 years to 54 years). They received one to three ASMs with stable dosages for at least 30 days before screening, and they experienced at least two drop seizures per week during the four‐week baseline period. Included participants were randomised to add‐on placebo or one of three doses of add‐on clobazam (0.25, 0.5, and 1.0 mg/kg/day), up to a maximum dosage of 40 mg/day. Treatment included a three‐week titration phase and a 12‐week maintenance phase followed by two to three weeks tapering or continuation in an open‐label extension. Baseline characteristics were comparable between groups, although the medium‐dose clobazam group had a lower mean baseline average weekly drop seizure rate (58.8; SD 119.6) compared with the low‐dose group (98.3; SD 198.5), high‐dose group (94.9; SD 152.2), and placebo group (95.6; SD 168.2). Most study participants in each group were of white ethnicity (57% to 71%). </p> <p>We included a post‐hoc analysis of <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a> as a subsidiary paper (<a href="./references#CD003277-bbs2-0061" title="PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]">Paolicchi 2015</a>). This post‐hoc analysis aimed to determine potential drug‐related effects on four behaviour domains of the Child Behaviour Checklist (CBCL): aggressive behaviour, anxious/depressed, attention problems, and somatic complaints (<a href="./references#CD003277-bbs2-0029" title="AchenbachTM . Manual for the Child Behavior Checklist/4–18 and 1991 Profile. Department of Psychiatry. University of Vermont, Burlington, VT, 1991.">Achenbach 1991</a>). </p> </section> <section id="CD003277-sec-0054"> <h5 class="title">Ohtsuka 2014</h5> <p><a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a> included 59 randomised children and adults (aged between 4 years and 30 years), and was conducted in Japan. Included participants experienced at least 90 seizures during the 28 days before the baseline period. They took one to three background ASMs at baseline. The participants were randomised to either add‐on rufinamide (doses titrated according to a predetermined schedule based on body weight, with the target dose maintained during the maintenance period) or add‐on placebo. This study consisted of four phases: a four‐week baseline, a two‐week titration, a 10‐week maintenance, and either a follow‐up visit or entry into an open‐label extension. Baseline characteristics were comparable between groups although there was a relatively higher concomitant use of lamotrigine in the placebo group and relatively higher concomitant use of clobazam in the rufinamide group. Participants' ethnicity was not reported in this study. </p> </section> <section id="CD003277-sec-0055"> <h5 class="title">Sachdeo 1999</h5> <p><a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a> was conducted at 12 centres in the USA. The study included 98 randomised children and young adults (aged over one year to under 30 years). Included participants experienced seizure types including drop attacks and atypical absence seizures; they had a frequency of at least 60 seizures during the month prior to the baseline phase, while being maintained on one or two standard ASMs. The trial consisted of a baseline phase of four weeks and an 11‐week treatment phase that included three weeks titration and eight weeks maintenance. The participants were titrated up to a dose of 6 mg/kg/day or their maximal tolerated dosage of either add‐on topiramate or add‐on placebo over the first three weeks of the treatment period. Of note, concomitant treatment with felbamate was prohibited part way through the study, due to adverse effects. Baseline characteristics were comparable between groups, although there was a slightly higher proportion of males in the topiramate group. Both groups largely involved participants of white ethnicity (more than 80%). </p> </section> <section id="CD003277-sec-0056"> <h5 class="title">Thiele 2018</h5> <p><a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a> was conducted at 24 clinical sites in the USA (17 sites), the Netherlands (one site), and Poland (six sites). It included 171 children and adults (aged two years to 45 years). The study participants experienced more than one type of generalised seizure, including drop seizures, for at least six months. At baseline, they took one to four ASMs, and had at least two drop seizures per week during the four‐week baseline period. Participants were randomised to add‐on cannabidiol 20 mg/kg (given as oral solution) or matching add‐on placebo solution administered orally in two equally divided doses. The study duration was 14 weeks, which included two weeks of dose escalation (starting at a daily dose of 2.5 mg/kg, followed by a maintenance period of 12 weeks), a tapering period of up to 10 days, and a four‐week safety follow‐up period. Baseline characteristics were comparable between groups, although the placebo group had a higher proportion of participants on a ketogenic diet as a concomitant intervention (12% versus 5%). Both groups largely involved participants of white ethnicity (more than 87%). </p> </section> </section> <section id="CD003277-sec-0057"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD003277-sec-0185" title="">Characteristics of excluded studies</a>. </p> <p>We excluded eight studies from the search results for this updated review. We excluded two previously included studies that compared different doses of the same ASM (<a href="./references#CD003277-bbs2-0013" title="ConryJA , NgYT , PaolicchiJM , KernitskyL , MitchellWG , RitterFJ , et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia2009;50(5):1158-66. [PMID: 19170737]">Conry 2009</a> and <a href="./references#CD003277-bbs2-0014" title="InanagaK , KumashiroH , FukyamaY , OhtaharaS , ShirouzuM . Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia1989;30(4):438-45. [PMID: 2502385]">Inanaga 1989</a>). Three studies were judged not to be randomised trials (<a href="./references#CD003277-bbs2-0015" title="OletskyH , KelleyK , StertzB , Reeves-TyerP , FlaminiR , MalowB , et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):155, Abstract no: 6.13. ">Oletsky 1996</a>; <a href="./references#CD003277-bbs2-0016" title="PerryMS . Don't fear the reefer - evidence mounts for plant-based cannabidiol as treatment for epilepsy. Epilepsy Currents2019;19(2):93-5. [DOI: 10.1177/1535759719835671] [PMID: 30955420]">Perry 2019</a>; <a href="./references#CD003277-bbs2-0019" title="VigevanoF , CilioMR , AntoniniL . Clinical experience with Felbamate in paediatric age. In: Bollettino - Lega Italiana Contro L'Epilessia. Vol. 86-87. 1994:63-6. [DOI: 10.1016/s0920-1211(01)00290-x]">Vigevano 1994</a>). We also considered studies excluded from the previous version of this review, and agreed on the exclusion of three further studies. We excluded these studies because incomplete reporting for participants with LGS meant that the data were not usable (<a href="./references#CD003277-bbs2-0012" title="BattagliaA , FerrariAR , GuerriniR . Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy. Brain and Development1991;13(4):217-22. [PMID: 1957968]">Battaglia 1991</a>; <a href="./references#CD003277-bbs2-0017" title="VajdaFJ , BladinPF , ParsonsBJ . Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clinical and Experimental Neurology1985;21:177-82. [PMID: 3843217]">Vajda 1985</a> ; <a href="./references#CD003277-bbs2-0018" title="VassellaF , RudebergA , Da SilvaV , PavlincovaE . Double-blind study on the anticonvulsive effect of phenobarbital and valproate in the Lennox syndrome [Doppletblind-Untersuchung uber die antikonvulsive Wirkung von Phenobarbital und Valproat beim Lennox-Syndrom]. Schweizerische Medizinische Wochenschrift1978;108(19):713-6. [PMID: 347569]">Vassella 1978</a>). We did not attempt to contact authors for additional data from these studies, which were published between 29 and 42 years ago. We included one previously excluded study as a subsidiary publication relating to the <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>. </p> </section> </section> <section id="CD003277-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>We have reported 'Risk of bias' assessments for each study in <a href="./references#CD003277-sec-0184" title="">Characteristics of included studies</a>. <a href="#CD003277-fig-0002">Figure 2</a> summarises the review authors' 'Risk of bias' assessments. Only two included studies of add‐on cannabidiol had published protocols (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). Based on the available information, we identified a high risk of selective reporting bias in five of the 11 RCTs (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>), three of which were included in the previous version of the review (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). In three of the 11 RCTs, we identified a high risk of bias associated with incomplete outcome data (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>; <a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>), two of which were included in the previous version of this review (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>); the more recent study had a relatively long follow up of two years (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>). We identified a high risk of bias due to the exclusion of 'non‐responders' in the initial open phase of one study (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>). </p> <div class="figure" id="CD003277-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003277-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>For outcomes included in the 'Summary of findings' tables, we assessed risk of bias at the outcome level. However, we downgraded outcomes for study limitations in one comparison that was stopped prematurely and judged to have a very serious risk of bias due to a combination of selective reporting and incomplete data (<a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). </p> <section id="CD003277-sec-0059"> <h4 class="title">Allocation</h4> <p>We assessed all eleven included studies to have a low risk of selection bias associated with random sequence generation. In terms of allocation concealment, we judged six of the eleven included studies to have a low risk of selection bias and five studies as having an unclear risk of selection bias. </p> </section> <section id="CD003277-sec-0060"> <h4 class="title">Blinding</h4> <p>We judged two of the eleven included studies to have a low risk of performance bias and detection bias, and nine studies to have an unclear risk of performance bias and detection bias. </p> </section> <section id="CD003277-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>We judged five of the eleven included studies to have a low risk of attrition bias, three studies as having an unclear risk and three studies as having a high risk of attrition bias. </p> </section> <section id="CD003277-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We judged six of the eleven included studies to have a low risk of reporting bias and five as having a high risk of reporting bias. </p> </section> <section id="CD003277-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other potential sources of bias in the eleven included studies.</p> </section> </section> <section id="CD003277-sec-0064"> <h3 class="title" id="CD003277-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD003277-tbl-0001"><b>Summary of findings 1</b> Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0002"><b>Summary of findings 2</b> Cinromide plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0003"><b>Summary of findings 3</b> Clobazam (low, medium and high doses) plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0004"><b>Summary of findings 4</b> Felbamate plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0005"><b>Summary of findings 5</b> Lamotrigine plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0006"><b>Summary of findings 6</b> Rufinamide plus ASMs compared to placebo plus ASMs</a>; <a href="./full#CD003277-tbl-0007"><b>Summary of findings 7</b> Rufinamide plus ASMs compared to other ASM plus ASMs</a>; <a href="./full#CD003277-tbl-0008"><b>Summary of findings 8</b> Topiramate plus ASMs compared to placebo plus ASMs</a> </p> <p>See: <a href="./full#CD003277-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD003277-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003277-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD003277-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD003277-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD003277-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD003277-tbl-0007">summary of findings Table 7</a>; and <a href="./full#CD003277-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD003277-sec-0065"> <h4 class="title">Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs versus placebo plus ASMs</h4> <p>Two studies contributed data for this comparison (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). </p> <p><a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> evaluated cannabidiol 10 mg/kg/day and 20 mg/kg/day, whereas <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a> evaluated only 20 mg/kg/day. </p> <p>In <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>, "A total of 13 patients (6%) discontinued either cannabidiol (11 patients) or placebo (2 patients); in 7 of the 11 patients who discontinued cannabidiol, the treatment was discontinued because of adverse events." In <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>, "14 patients in the cannabidiol group and one in the placebo group (9%) withdrew from the trial; in nine (60%) of these patients, adverse events were the primary reason for study discontinuation." </p> <section id="CD003277-sec-0066"> <h5 class="title">Number of participants free from drop seizures during the treatment phase</h5> <p>No participants were free from drop seizures (one study; 225 participants; <a href="./references#CD003277-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD003277-sec-0067"> <h5 class="title">Number of participants with ≥ 75% reduction in drop seizures during the treatment phase </h5> <p>The RR was 3.51 (95% CI 1.24 to 9.92) in favour of the cannabidiol regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0004" title="">Analysis 1.2</a>). </p> </section> <section id="CD003277-sec-0068"> <h5 class="title">Number of participants with ≥ 50% reduction in drop seizures during the treatment phase </h5> <p>The RR was 2.12 (95% CI 1.48 to 3.03) in favour of the cannabidiol regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD003277-sec-0069"> <h5 class="title">Number of participants with ≥ 25% reduction in drop seizures during the treatment phase </h5> <p>The RR was 1.45 (95% CI 1.19 to 1.78) in favour of the cannabidiol regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD003277-sec-0070"> <h5 class="title">Number of participants with &gt; 0% to &lt; 25% reduction in drop seizures during the treatment phase </h5> <p>The RR was 1.58 (95% CI 0.85 to 2.93) in favour of the cannabidiol regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 225 participants; <a href="./references#CD003277-fig-0007" title="">Analysis 1.5</a>). </p> </section> <section id="CD003277-sec-0071"> <h5 class="title">Number of participants with &gt; 0% to &lt; 25% increase in drop seizures during the treatment phase </h5> <p>The RR was 1.40 (95% CI 0.66 to 3.00) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 225 participants; <a href="./references#CD003277-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD003277-sec-0072"> <h5 class="title">Number of participants with &gt; 25% increase in drop seizures during the treatment phase</h5> <p>The RR was 0.71 (95% CI 0.33 to 1.53) in favour of the cannabidiol regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 225 participants; <a href="./references#CD003277-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD003277-sec-0073"> <h5 class="title">Number of participants with improvement in the patient and caregiver Global Impression of Care scale </h5> <p>The RR was 1.52 (95% CI 1.22 to 1.89) in favour of the cannabidiol regimen (two studies; 392 participants; <a href="./references#CD003277-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD003277-sec-0074"> <h5 class="title">Number of participants free from drop seizures during the maintenance phase</h5> <p>The Peto OR was 7.76 (99% CI 0.75 to 79.85) in favour of the cannabidiol regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 170 participants; <a href="./references#CD003277-fig-0011" title="">Analysis 1.9</a>). </p> </section> <section id="CD003277-sec-0075"> <h5 class="title">Number of participants with ≥ 75% reduction in drop seizures during the maintenance phase </h5> <p>The RR was 2.86 (95% CI 1.28 to 6.40) in favour of the cannabidiol regimen (one study; 170 participants; <a href="./references#CD003277-fig-0012" title="">Analysis 1.10</a>). </p> </section> <section id="CD003277-sec-0076"> <h5 class="title">Number of participants with ≥ 50% reduction in drop seizures during the maintenance phase </h5> <p>The RR was 1.95 (95% CI 1.25 to 3.05) in favour of the cannabidiol regimen (one study; 170 participants; <a href="./references#CD003277-fig-0013" title="">Analysis 1.11</a>). </p> </section> <section id="CD003277-sec-0077"> <h5 class="title">Number of participants with ≥ 25% reduction in drop seizures during the maintenance phase </h5> <p>The RR was 1.35 (95% CI 1.02 to 1.78) in favour of the cannabidiol regimen (one study; 170 participants; <a href="./references#CD003277-fig-0014" title="">Analysis 1.12</a>). </p> </section> <section id="CD003277-sec-0078"> <h5 class="title">Number of participants with adverse events</h5> <p>The RR was 1.24 (95% CI 1.11 to 1.38) in favour of the placebo regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0015" title="">Analysis 1.13</a>). </p> </section> <section id="CD003277-sec-0079"> <h5 class="title">Number of participants with treatment‐related adverse events</h5> <p>The RR was 1.81 (95% CI 1.29 to 2.54) in favour of the placebo regimen (one study; 171 participants; <a href="./references#CD003277-fig-0016" title="">Analysis 1.14</a>). </p> </section> <section id="CD003277-sec-0080"> <h5 class="title">Number of participants with serious adverse events</h5> <p>The RR was 4.94 (95% CI 1.76 to 13.85) in favour of the placebo regimen (one study; 171 participants; <a href="./references#CD003277-fig-0017" title="">Analysis 1.15</a>). </p> </section> <section id="CD003277-sec-0081"> <h5 class="title">Number of participants with adverse events leading to dose reduction</h5> <p>The RR was 5.93 (95% CI 0.73 to 48.22) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 171 participants; <a href="./references#CD003277-fig-0018" title="">Analysis 1.16</a>). </p> </section> <section id="CD003277-sec-0082"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>The RR was 6.62 (95% CI 1.56 to 28.15) in favour of the placebo regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0019" title="">Analysis 1.17</a>). We assessed the certainty of the evidence for this outcome to be high (<a href="./full#CD003277-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD003277-sec-0083"> <h5 class="title">Death</h5> <p>The Peto OR was 7.30 (99% CI 0.04 to 1261.58) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 171 participants; <a href="./references#CD003277-fig-0020" title="">Analysis 1.18</a>). </p> </section> </section> <section id="CD003277-sec-0084"> <h4 class="title">Cinromide plus ASMs versus placebo plus ASMs</h4> <p>One study contributed data for this comparison (<a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). This study was terminated prematurely "when it was clear to the sponsor that cinromide was not effective"; only efficacy data collected before study interruption were included in the analysis. This study also reported changes in adjuvant ASM dosage following adverse events for 62% of the cinromide group and 27% of the placebo group. </p> <section id="CD003277-sec-0085"> <h5 class="title">Number of participants free from all seizures</h5> <p>No participants were free from seizures (one study; 56 participants; <a href="./references#CD003277-fig-0021" title="">Analysis 2.1</a>). We downgraded the certainty of evidence for this outcome twice for study limitations because there was a high risk of bias for incomplete data and twice for imprecision because the study was not powered to detect a between‐group difference in zero event outcomes. Our certainty in the evidence for this outcome was very low (<a href="./full#CD003277-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003277-sec-0086"> <h5 class="title">Number of participants with ≥ 75% reduction in mean weekly seizures</h5> <p>The Peto OR was 9.35 (99% CI 0.45 to 194.96) in favour of the cinromide regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0022" title="">Analysis 2.2</a>). We downgraded the certainty of evidence for this outcome twice for study limitations because there was a high risk of bias for incomplete data and twice for imprecision because the effect estimate has a very wide CI. Our certainty in the evidence for this outcome was very low (<a href="./full#CD003277-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003277-sec-0087"> <h5 class="title">Number of participants with ≥ 50% reduction in mean weekly seizures</h5> <p>The RR was 1.15 (95% CI 0.47 to 2.86) in favour of the cinromide regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0023" title="">Analysis 2.3</a>). We downgraded the certainty of evidence for this outcome twice for study limitations because there was a high risk of bias for incomplete data and twice for imprecision because the effect estimate has a very wide CI. Our certainty in the evidence for this outcome was very low (<a href="./full#CD003277-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003277-sec-0088"> <h5 class="title">Number of participants with ≥ 25% reduction in mean weekly seizures</h5> <p>The RR was 1.07 (95% CI (95% CI 0.59 to 1.91) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0024" title="">Analysis 2.4</a>). </p> </section> <section id="CD003277-sec-0089"> <h5 class="title">Number of participants with ≥ 0% to &lt; 25% reduction in mean weekly seizures</h5> <p>The RR was 1.15 (95% CI 0.42 to 3.14) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0025" title="">Analysis 2.5</a>). </p> </section> <section id="CD003277-sec-0090"> <h5 class="title">Number of participants with ≥ 0% to &lt; 25% increase in mean weekly seizures</h5> <p>The RR was 0.87 (95% CI 0.21 to 3.52) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0026" title="">Analysis 2.6</a>). </p> </section> <section id="CD003277-sec-0091"> <h5 class="title">Number of participants with &gt; 25% increase in mean weekly seizures</h5> <p>The RR was 0.82 (95% CI 0.30 to 2.29) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0027" title="">Analysis 2.7</a>). </p> </section> <section id="CD003277-sec-0092"> <h5 class="title">Number of participants with improvement in global evaluation (at week 12, 18 and 24)</h5> <p>Week 12: the RR was 0.99 (95% CI 0.56 to 1.74) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0028" title="">Analysis 2.8</a>). </p> <p>Week 18: the RR was 0.80 (95% CI 0.41 to 1.56) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0028" title="">Analysis 2.8</a>). </p> <p>Week 24: the RR was 1.28 (95% CI 0.62 to 2.66) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0028" title="">Analysis 2.8</a>). </p> </section> <section id="CD003277-sec-0093"> <h5 class="title">Number of participants with no change in global evaluation (at week 12, 18 and 24)</h5> <p>Weeks 12 and 18: the RR was 0.91 (0.50 to 1.64) in favour of the cinromide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0029" title="">Analysis 2.9</a>). </p> <p>Week 24: the RR was 1.03 (95% CI 0.46 to 2.27) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0029" title="">Analysis 2.9</a>). </p> </section> <section id="CD003277-sec-0094"> <h5 class="title">Number of participants with worsening in global evaluation (at week 12, 18 and 24)</h5> <p>Week 12: the RR was 3.46 (95% CI 0.38 to 31.28) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0030" title="">Analysis 2.10</a>). </p> <p>Week 18: the RR was 4.62 (95% CI 0.55 to 38.74) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0030" title="">Analysis 2.10</a>). </p> <p>Week 24: the Peto OR was 9.09 (99% CI 0.17 to 475.60) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 56 participants; <a href="./references#CD003277-fig-0031" title="">Analysis 2.11</a>). </p> </section> <section id="CD003277-sec-0095"> <h5 class="title">Death</h5> <p>No deaths were reported in the study.</p> </section> </section> <section id="CD003277-sec-0096"> <h4 class="title">Clobazam plus ASMs versus placebo plus ASMs</h4> <p>One study contributed data for this comparison (<a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>). According to study authors, "the most common reasons for discontinuing the study were lack of efficacy for placebo‐treated patients and adverse events for clobazam‐treated patients." In the placebo group, 30.5% of participants discontinued the study. Ten participants discontinued treatment due to lack of efficacy, four due to the request of the participant, parent or caregiver, two due to side effects, and two participants were lost to follow up. With clobazam, 13.8% of participants discontinued from the low‐dose group, 27.4% discontinued from the medium‐dose group, and 30.5% discontinued from the high‐dose group. Twenty‐four participants treated with add‐on clobazam discontinued due to side effects, five discontinued due to lack of efficacy, five discontinued due to the request of the participant, parent or caregiver, five discontinued for other reasons such as protocol violations; and four participants were lost to follow up. </p> <p>A post‐hoc study investigated aggression‐related adverse events that occurred after the first dose of study drug and within 30 days after the last dose of study drug and found no difference between clobazam and placebo (RR 1.89, 95% CI 0.69 to 5.19). Among the 23 participants randomised to rufinamide who experienced aggression‐related adverse events, five had a history of aggression or behavioural problems. Among the four participants randomised to placebo who experienced aggression‐related adverse events, one person had a history of aggression or behavioural problems. </p> <section id="CD003277-sec-0097"> <h5 class="title">Number of participants free from drop seizures</h5> <p>The RR was 4.10 (95% CI 1.00 to 16.83) in favour of the clobazam regimen (one study; 217 participants; <a href="./references#CD003277-fig-0032" title="">Analysis 3.1</a>). </p> </section> <section id="CD003277-sec-0098"> <h5 class="title">Number of participants with ≥ 75% reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </h5> <p>The RR was 4.04 (95% CI 1.85 to 8.79) in favour of the clobazam regimen (one study; 217 participants; <a href="./references#CD003277-fig-0033" title="">Analysis 3.2</a>). </p> </section> <section id="CD003277-sec-0099"> <h5 class="title">Number of participants with ≥ 50% reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </h5> <p>The RR was 1.88 (95% CI 1.26 to 2.81) in favour of the clobazam regimen (one study; 217 participants; <a href="./references#CD003277-fig-0034" title="">Analysis 3.3</a>). </p> </section> <section id="CD003277-sec-0100"> <h5 class="title">Number of participants with ≥ 25% reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </h5> <p>The RR was 1.54 (95% CI 1.17 to 2.03) in favour of the clobazam regimen (one study; 217 participants; <a href="./references#CD003277-fig-0035" title="">Analysis 3.4</a>). </p> </section> <section id="CD003277-sec-0101"> <h5 class="title">Number of participants with adverse events</h5> <p>The RR was 1.17 (95% CI.097 to 2.03) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 238 participants; <a href="./references#CD003277-fig-0036" title="">Analysis 3.5</a>). </p> </section> <section id="CD003277-sec-0102"> <h5 class="title">Number of participants with adverse events leading to dose reduction</h5> <p>The RR was 9.23 (95% CI 1.28 to 66.37) in favour of the placebo regimen (one study; 238 participants; <a href="./references#CD003277-fig-0037" title="">Analysis 3.6</a>). </p> </section> <section id="CD003277-sec-0103"> <h5 class="title">Number of participants with aggression‐related adverse events</h5> <p>The RR was 1.89 (95% CI 0.69 to 5.19) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 194 participants; <a href="./references#CD003277-fig-0038" title="">Analysis 3.7</a>). </p> </section> <section id="CD003277-sec-0104"> <h5 class="title">Number of participants with serious adverse events</h5> <p>The RR was 2.31 (95% CI 0.54 to 9.86) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 238 participants; <a href="./references#CD003277-fig-0039" title="">Analysis 3.8</a>). </p> </section> <section id="CD003277-sec-0105"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>The RR was 4.12 (95% CI 1.01 to 16.87) in favour of the placebo regimen (one study; 238 participants; <a href="./references#CD003277-fig-0040" title="">Analysis 3.9</a>). We assessed the certainty of the evidence for this outcome to be high (<a href="./full#CD003277-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD003277-sec-0106"> <h5 class="title">Death</h5> <p>There were no deaths in this study (one study; 238 participants; <a href="./references#CD003277-fig-0041" title="">Analysis 3.10</a>). </p> </section> </section> <section id="CD003277-sec-0107"> <h4 class="title">Felbamate plus ASMs versus placebo plus ASMs</h4> <p>One study contributed data for this comparison (<a href="./references#CD003277-bbs2-0004" title="DodsonWE . Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993;34(Suppl 7):S18-24. [PMID: 8243374]Felbamate Study Group in Lennox Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). New England Journal of Medicine1993;328(1):29-33. [PMID: 8347179]GarofaloEA , OlsonLD , SackellaresJC , ChildsJ , TornowMA . Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia1990;31(5):619. RitterF , DreifussFE , SackellaresJC , ShieldsD , FrenchJ , DodsonWE , et al. A double-blind trial of felbamate in Lennox-Gastaut syndrome. Epilepsia1991;32(Suppl 3):13. ">Felbamate Study Group 1993</a>). One participant had treatment stopped because of somnolence and ataxia in the felbamate group and one because of pancreatitis in the placebo group. According to retrospective analysis, "Approximately 50% of patients randomised to FBM obtained at least a 50% reduction in seizure frequency compared with about 15% receiving placebo" (<a href="./references#CD003277-bbs2-0053" title="JensenPK . Felbamate in the treatment of Lennox-Gastaut syndrome. Epilepsia1994;35(Suppl 5):S54-7. [PMID: 8039473]">Jensen 1994</a>). </p> <section id="CD003277-sec-0108"> <h5 class="title">Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) </h5> <p>Treatment phase: the RR was 2.92 (95% CI 0.32 to 26.77) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 73 participants; <a href="./references#CD003277-fig-0042" title="">Analysis 4.1</a>). We downgraded the certainty of evidence for this outcome twice for imprecision (from high to low) because the effect estimate has a very wide CI (<a href="./full#CD003277-tbl-0004">summary of findings Table 4</a>). </p> <p>Maintenance phase: the RR was 5.84 (95% CI 0.74 to 46.11) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 73 participants; <a href="./references#CD003277-fig-0042" title="">Analysis 4.1</a>). </p> </section> <section id="CD003277-sec-0109"> <h5 class="title">Number of participants free from all seizures</h5> <p>Treatment phase: No participants were free from seizures (one study; 73 participants; <a href="./references#CD003277-fig-0043" title="">Analysis 4.2</a>). We downgraded the certainty of the evidence twice for imprecision (from high to low) because the study was not powered to detect a between‐group difference in zero event outcomes (<a href="./full#CD003277-tbl-0004">summary of findings Table 4</a>). </p> <p>Maintenance phase: the RR was 3.89 (95% CI 0.46 to 33.17) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 73 participants; <a href="./references#CD003277-fig-0044" title="">Analysis 4.3</a>). </p> </section> <section id="CD003277-sec-0110"> <h5 class="title">Number of participants free from atonic seizures</h5> <p>Treatment phase: the Peto OR was 6.43 (99% CI 0.30 to 137.10) in favour of the felbamate regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 50 participants; <a href="./references#CD003277-fig-0045" title="">Analysis 4.4</a>). </p> <p>Maintenance phase: the Peto OR was 6.99 (99% CI 0.62 to 78.73) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 50 participants; <a href="./references#CD003277-fig-0045" title="">Analysis 4.4</a>). </p> </section> <section id="CD003277-sec-0111"> <h5 class="title">Number of participants free from tonic‐clonic seizures</h5> <p>Treatment phase: the RR was 1.63 (95% CI 0.17 to 15.99) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 29 participants; <a href="./references#CD003277-fig-0046" title="">Analysis 4.5</a>. </p> <p>Maintenance phase: the RR was 5.69 (95% CI 0.80 to 40.51) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 29 participants; <a href="./references#CD003277-fig-0046" title="">Analysis 4.5</a>). </p> </section> <section id="CD003277-sec-0112"> <h5 class="title">Number of participants with severe side effects</h5> <p>The RR was 2.59 (95% CI 0.75 to 9.01) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 73 participants; <a href="./references#CD003277-fig-0047" title="">Analysis 4.6</a>). </p> </section> <section id="CD003277-sec-0113"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>The RR was 0.97 (95% CI 0.06 to 14.97) in favour of the felbamate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 73 participants; <a href="./references#CD003277-fig-0048" title="">Analysis 4.7</a>). We downgraded the certainty of evidence for this outcome twice for imprecision (from high to low) because the effect estimate has a very wide CI (<a href="./full#CD003277-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD003277-sec-0114"> <h5 class="title">Death</h5> <p>No deaths were reported in the study.</p> </section> </section> <section id="CD003277-sec-0115"> <h4 class="title">Lamotrigine plus ASMs versus placebo plus ASMs</h4> <p>Two studies assessed this comparison (<a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a>; <a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>) but only one contributed usable data for this review (<a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>). </p> <p><a href="./references#CD003277-bbs2-0003" title="ErikssonAS , NergardhA , BoreusL , KnutssonE . Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy. Epilepsia1995;36(Suppl 3):S110-1. ErikssonAS , NergardhA , HoppuK . The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study. Epilepsia1998;39(5):495-501. [PMID: 9596201]">Eriksson 1998</a> excluded "non‐responders" involved in an initial open phase of treatment from participating in the randomised study. The study also incompletely reported efficacy and tolerability outcomes for the subgroup of participants with LGS. The study reported that seven of the 20 children with LGS responded to treatment with &gt; 50% seizure reduction, three children with &gt; 75% seizure reduction, and two children became seizure free. However, individual data were only reported for 13 children with LGS, and no data were provided for the baseline number of seizures prior to crossover. In terms of adverse events, the study only reported data for the overall study population with refractory generalised epilepsy. </p> <p>In this study, seven out of 13 children with LGS entered into the double‐blind phase of the trial showed improvement in the lamotrigine phase compared with the placebo phase, with one child showing a 100% reduction in their seizures. Three participants on lamotrigine had treatment withdrawn (23%), one had deterioration of seizure control, the other two developed a rash. Seven participants receiving placebo had treatment withdrawn (54%), six because of deterioration in seizure control and one other developed a rash. </p> <p>In <a href="./references#CD003277-bbs2-0007" title="BillardC , MotteJ , ArvidssonD , TrevathanE , TalladaiM , CamposJ , et al. Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 4):92. GallagherJ , MullensL , RigdonG , DonahueR . Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome. Neurology1997;48(3):A109. MotteJ , TrevathanE , ArvidssonJF , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine1997;337(25):1807-12. [PMID: 9400037]MullensL , GallagherJ , ManascoP , for the Lamictal Lennox-Gastaut Study Group. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia1996;37(Suppl 5):163, abstract no: 6.47. TrevathanE , MotteJ , ArvidssonJ , ManascoP , MullensL . Safety and tolerability of adjunctive Lamictal® for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia1996;37(Suppl 5):202, abstract no: I.3. ">Motte 1997</a>, 12% of participants discontinued from the study. "Seven patients in the lamotrigine group stopped treatment early, four because of protocol violations and three because of adverse events. Fourteen patients in the placebo group did not complete the study: seven had adverse events, three had protocol violations, two had a deterioration in the control of seizures, one failed to return for follow‐up, and the parents of one patient withdrew their consent." </p> <section id="CD003277-sec-0116"> <h5 class="title">Number of participants with ≥ 50% median reduction in all seizures</h5> <p>The RR was 2.12 (95% CI 1.19 to 3.76) in favour of the lamotrigine regimen (one study; 167 participants; <a href="./references#CD003277-fig-0049" title="">Analysis 5.1</a>). We assessed the certainty of the evidence for this outcome to be high (<a href="./full#CD003277-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD003277-sec-0117"> <h5 class="title">Number of participants with &gt; 25% to &lt; 50% median reduction in all seizures</h5> <p>The RR was 1.41 (95% CI 0.80 to 2.47) in favour of the lamotrigine regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 167 participants; <a href="./references#CD003277-fig-0050" title="">Analysis 5.2</a>). </p> </section> <section id="CD003277-sec-0118"> <h5 class="title">Number of participants with either 0 to ≤ 25% median reduction or an increase in all seizures </h5> <p>The RR was 0.61 (95% CI 0.45 to 0.83) in favour of the lamotrigine regimen (one study; 167 participants; <a href="./references#CD003277-fig-0051" title="">Analysis 5.3</a>). </p> </section> <section id="CD003277-sec-0119"> <h5 class="title">Number of participants with ≥ 50% median reduction in drop attacks</h5> <p>The RR was 1.66 (95% CI 1.02 to 2.70) in favour of the lamotrigine regimen (one study; 164 participants; <a href="./references#CD003277-fig-0052" title="">Analysis 5.4</a>). </p> </section> <section id="CD003277-sec-0120"> <h5 class="title">Number of participants with &gt; 25% to &lt; 50% median reduction in drop attacks</h5> <p>The RR was 1.61 (95% CI 0.87 to 2.99) in favour of the lamotrigine regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 164 participants; <a href="./references#CD003277-fig-0053" title="">Analysis 5.5</a>). </p> </section> <section id="CD003277-sec-0121"> <h5 class="title">Number of participants in with either ≤ 25% median reduction or an increase in drop attacks </h5> <p>The RR was 0.60 (95% CI 0.43 to 0.85) in favour of the lamotrigine regimen (one study; 164 participants; <a href="./references#CD003277-fig-0054" title="">Analysis 5.6</a>). </p> </section> <section id="CD003277-sec-0122"> <h5 class="title">Number of participants with ≥ 50% median reduction in tonic‐clonic seizures</h5> <p>The RR was 2.13 (95% CI 1.21 to 3.75) in favour of the lamotrigine regimen (one study; 124 participants; <a href="./references#CD003277-fig-0055" title="">Analysis 5.7</a>. </p> </section> <section id="CD003277-sec-0123"> <h5 class="title">Number of participants with &gt; 25% to &lt; 50% median reduction in tonic‐clonic seizures</h5> <p>The RR was 0.91 (95% CI 0.33 to 2.57) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 124 participants; <a href="./references#CD003277-fig-0056" title="">Analysis 5.8</a>. </p> </section> <section id="CD003277-sec-0124"> <h5 class="title">Number of participants with either 0 to ≤ 25% median reduction or an increase in tonic‐clonic seizures </h5> <p>The RR was 0.68 (95% CI 0.49 to 0.93) in favour of the lamotrigine regimen (one study; 124 participants; <a href="./references#CD003277-fig-0057" title="">Analysis 5.9</a>). </p> </section> <section id="CD003277-sec-0125"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>The RR was 0.49 (95% CI 0.13 to 1.82) in favour of the lamotrigine regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 169 participants; <a href="./references#CD003277-fig-0058" title="">Analysis 5.10</a>). We downgraded the certainty of evidence for this outcome twice for imprecision because the effect estimate has a very wide CI. Our certainty in the evidence for this outcome was low (<a href="./full#CD003277-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD003277-sec-0126"> <h5 class="title">Death</h5> <p>No deaths were reported in the study.</p> </section> </section> <section id="CD003277-sec-0127"> <h4 class="title">Rufinamide plus ASMs versus placebo plus ASMs</h4> <p>Two studies contributed data for this comparison (<a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>; <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>). In <a href="./references#CD003277-bbs2-0005" title="GlauserT , KlugerG , KraussG , ArroyoS . Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study. Epilepsia2007;48(Suppl 7):156, abstract no: p415. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Epilepsia2005;46(Suppl 6):408, abstract no: p1356. GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology2008;70(21):1950-8. [DOI: 10.1212/01.wnl.0000303813.95800.0d] [PMID: 18401024]GlauserT , KlugerG , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Annals of Neurology2005;58(Suppl 9):S92, abstract no: M15. GlauserT , KlugerG , SachedoR , KraussG , PerdomoC , ArroyoS . Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology2005;64(10):1826, abstract no: LBS.001. GlauserT , Santana BV , WangW , NarurkarM . Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome. Epilepsia2009;50(Suppl 11):261, abstract no: 2.229. KlugerG , GlauserT , KraussG , SeeruthunR , PerdomoC , ArroyoS . Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurologica Scandinavica2010;122(3):202-8. [DOI: 10.1111/j.1600-0404.2010.01334.x] [PMID: 20199521]KlugerG , GlauserT , SachdeoR , KraussG , PerdomoC , ArroyoS . Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia2006;47(Suppl 3):139, abstract no: p537. KraussGL , GlauserT , KlugerG , ArroyoS . Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):359, abstract no: 3.303. McMurrayR , StrianoP . Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurology &amp; Therapy2016;5(1):35-43. [DOI: 10.1007/s40120-016-0041-9] [PMID: 26861566]StrianoP , McMurrayR . Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial. Epilepsia2015;56(Suppl 1):211, Abstract no: p0860. [DOI: 10.1111/epi.13241]">Glauser 2008</a>, 15 participants (11%) discontinued from the study. "Ten patients in the rufinamide group discontinued therapy during the double‐blind phase because of adverse events (n = 6), unsatisfactory therapeutic effect (n = 3), or withdrawal of consent (n = 1). Five patients in the placebo group did not complete the study because of protocol violations (n = 2), unsatisfactory therapeutic effect (n = 1), administrative problems (n = 1), or withdrawal of consent (n = 1)." </p> <p>In <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>, "One patient assigned to the rufinamide group was excluded from the efficacy analysis due to inappropriate diagnosis." </p> <section id="CD003277-sec-0128"> <h5 class="title">Number of participants with ≥ 50% reduction in all seizures</h5> <p>The RR was 2.84 (95% CI 1.31 to 6.18) in favour of the rufinamide regimen (one study; 138 participants; <a href="./references#CD003277-fig-0059" title="">Analysis 6.1</a>). We assessed the certainty of the evidence for this outcome to be high (<a href="./full#CD003277-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD003277-sec-0129"> <h5 class="title">Number of participants with ≥ 75% reduction in tonic‐atonic seizures</h5> <p>The RR was 10.71 (95% CI 1.46 to 78.39) in favour of the rufinamide regimen (one study; 58 participants; <a href="./references#CD003277-fig-0060" title="">Analysis 6.2</a>). </p> </section> <section id="CD003277-sec-0130"> <h5 class="title">Number of participants with ≥ 50% reduction in tonic‐atonic seizures</h5> <p>The RR was 2.70 (95% CI 1.52 to 4.81) in favour of the rufinamide regimen (two studies; 191 participants; <a href="./references#CD003277-fig-0061" title="">Analysis 6.3</a>). </p> </section> <section id="CD003277-sec-0131"> <h5 class="title">Number of participants with ≥ 25% reduction in tonic‐atonic seizures</h5> <p>The RR was 1.88 (95% CI 0.93 to 3.77) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 58 participants; <a href="./references#CD003277-fig-0062" title="">Analysis 6.4</a>). </p> </section> <section id="CD003277-sec-0132"> <h5 class="title">Number of participants 'unchanged' (&lt; 25% reduction in tonic‐atonic seizures)</h5> <p>The RR was 1.38 (95% CI 0.59 to 3.20) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 58 participants; <a href="./references#CD003277-fig-0063" title="">Analysis 6.5</a>). </p> </section> <section id="CD003277-sec-0133"> <h5 class="title">Number of participants with increased tonic‐atonic seizures</h5> <p>The RR was 0.36 (95% CI 0.15 to 0.85) in favour of the rufinamide regimen (one study; 58 participants; <a href="./references#CD003277-fig-0064" title="">Analysis 6.6</a>). </p> </section> <section id="CD003277-sec-0134"> <h5 class="title">Number of participants with improvement in seizure severity rating</h5> <p>The RR was 1.74 (95% CI 1.13 to 2.68) in favour of the rufinamide regimen (one study; 135 participants; <a href="./references#CD003277-fig-0065" title="">Analysis 6.7</a>). </p> </section> <section id="CD003277-sec-0135"> <h5 class="title">Number of participants with adverse events</h5> <p>The RR was 1.13 (95% CI 0.86 to 1.50) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (two studies; 197 participants; <a href="./references#CD003277-fig-0066" title="">Analysis 6.8</a>). </p> </section> <section id="CD003277-sec-0136"> <h5 class="title">Number of participants with adverse events suspected to be treatment‐related</h5> <p>The RR was 1.27 (95% CI 0.90 to 1.79) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 138 participants; <a href="./references#CD003277-fig-0067" title="">Analysis 6.9</a>). </p> </section> <section id="CD003277-sec-0137"> <h5 class="title">Number of participants with serious adverse events</h5> <p>The RR was 0.86 (95% CI 0.13 to 5.97) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 138 participants; <a href="./references#CD003277-fig-0068" title="">Analysis 6.10</a>). </p> </section> <section id="CD003277-sec-0138"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>In <a href="./references#CD003277-bbs2-0009" title="OhtsukaY , YoshinagaH , ShirasakaY , TakayamaR , TakanoH , IyodaK . Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Research2014;108(9):1627-36. [PMID: 25219353]">Ohtsuka 2014</a>, four of 29 participants in the rufinamide group did not complete the study due to adverse events, and 1 of 30 participants in the placebo group discontinued due to an adverse event. It is unclear if a participant with an inappropriate diagnosis was one of the few withdrawals experiencing adverse events. RR 4.14 (CI 0.49 to 34.86) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 59 participants; <a href="./references#CD003277-fig-0069" title="">Analysis 6.11</a>). We downgraded the certainty of evidence for this outcome twice for imprecision because the effect estimate has a very wide CI. Our certainty in the evidence for this outcome was low (<a href="./full#CD003277-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD003277-sec-0139"> <h5 class="title">Death</h5> <p>No deaths were reported in the study.</p> </section> </section> <section id="CD003277-sec-0140"> <h4 class="title">Rufinamide plus ASMs versus other ASM plus ASMs</h4> <p>One study contributed data for this comparison (<a href="./references#CD003277-bbs2-0001" title="ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303. European Journal of Paediatric Neurology2019;23(1):126-35. [PMID: 30309816]ArzimanoglouA , FerreiraJ , SatlinA , OlhayeO , KumarD , DhaddaS , et al. Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results. Developmental Medicine and Child Neurology2017;59(Suppl 4):135-6, Abstract no: 242. [DOI: 10.1111/dmcn.13623]ArzimanoglouA , FerreiraJA , SatlinA , MendesS , WilliamsB , CritchleyD , et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. European Journal of Paediatric Neurology2016;20(3):393‐402. [DOI: 10.1016/j.ejpn.2015.12.015] [PMID: 26805435]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303. Epilepsia Open2019;4(2):275‐80. [DOI: 10.1002/epi4.12314] [PMID: 31168494]AuvinS , WilliamsB , McMurrayR , KumarD , PerdomoC , MalhotraM . Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS). Neurology2018;90(15 Suppl):Abstract no: P1.272. ">Arzimanoglou 2019</a>). Ten of 25 people (40%) in the rufinamide group discontinued treatment, primarily due to adverse events (n = 3), patient choice (n = 2), inadequate therapeutic effect (n = 2), or withdrawal of consent (n = 3). Eight of 12 people (67%) in the 'Any other ASM' group discontinued treatment, primarily due to loss to follow‐up (n = 1), patient choice (n = 1), inadequate therapeutic effect (n = 1), withdrawal of consent (n = 4) or other reason (n = 1). </p> <section id="CD003277-sec-0141"> <h5 class="title">Number of participants with treatment‐emergent adverse events</h5> <p>The RR was 1.06 (95% CI 0.79 to 1.41) in favour of the other ASM regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0070" title="">Analysis 7.1</a>). </p> </section> <section id="CD003277-sec-0142"> <h5 class="title">Number of participants with severe treatment‐emergent adverse events</h5> <p>The RR was 0.96 (95% CI 0.20 to 4.53) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0071" title="">Analysis 7.2</a>). </p> </section> <section id="CD003277-sec-0143"> <h5 class="title">Number of participants with serious treatment‐emergent adverse events</h5> <p>The RR was 0.96 (95% CI 0.42 to 2.19) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0072" title="">Analysis 7.3</a>). </p> </section> <section id="CD003277-sec-0144"> <h5 class="title">Number of participants with treatment‐emergent adverse events leading to study‐drug dose adjustment </h5> <p>Reduction: the Peto OR was 5.91 (99% CI 0.61 to 57.64) in favour of the other ASM regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants). </p> <p>Interruption: the Peto OR was 0.04 (99% CI 0.00 to 2.17) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0073" title="">Analysis 7.4</a>). </p> </section> <section id="CD003277-sec-0145"> <h5 class="title">Number of participants with treatment‐emergent adverse events leading to study discontinuation</h5> <p>The RR was 0.96 (95% CI 0.10 to 9.57) in favour of the rufinamide regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0074" title="">Analysis 7.5</a>). We downgraded the certainty of evidence for this outcome twice for imprecision (from high to low) because the effect estimate has a very wide CI (<a href="./full#CD003277-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD003277-sec-0146"> <h5 class="title">Death</h5> <p>The Peto OR was 4.39 (99% CI 0.02 to 1077.58) in favour of the other ASM regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 37 participants; <a href="./references#CD003277-fig-0075" title="">Analysis 7.6</a>). </p> </section> <section id="CD003277-sec-0147"> <h5 class="title">Child Behaviour Checklist Questionnaire</h5> <p>The MD was 2.60 points (95% CI ‐10.30 to 15.50) in favour of the other ASM regime, but the CI included the possibility of an effect favouring either treatment regimen (one study; 19 participants; <a href="./references#CD003277-fig-0076" title="">Analysis 7.7</a>). </p> </section> </section> <section id="CD003277-sec-0148"> <h4 class="title">Topiramate + ASMs versus placebo + ASMs</h4> <p>One study contributed data for this comparison (<a href="./references#CD003277-bbs2-0010" title="GlauserTA , LevisohnPM , RitterF , SachdeoRC . Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia2000;41(Suppl 1):S86-90. [PMID: 10768308]GlauserTA , SachdeoRC , RitterFJ , ReifeR , LimP , Topiramate YL Study Group. A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS). Epilepsia1997;38(Suppl 3):131. RitterFJ , GlauserTA , SachdeoRC , Shu-ChenW . Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia1998;39(Suppl 2):2-3. RitterFJ , SachdeoRC , GlauserTA , Topiramate YL Study Group. Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome. Epilepsia1997;38(Suppl 3):94. RitterFJ , Topiramate YL Study Group. Open-label treatment of Lennox-Gastaut syndrome with topiramate. Epilepsia1997;38(Suppl 3):37. SachdeoRC , GlauserTA , RitterF , ReifeR , LimP , PledgerG . A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology1999;52(9):1882-7. [PMID: 10371538]SachdeoS , SachdeoRC , KuglerS . An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia1996;37(Suppl 5):112, abstract no: 4.89. ">Sachdeo 1999</a>). Of the randomised participants, only one person was withdrawn (due to patient choice), from the topiramate group. </p> <section id="CD003277-sec-0149"> <h5 class="title">Number of participants with ≥ 75% reduction in all seizures</h5> <p>The Peto OR was 8.22 (99% CI 0.60 to 112.62) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 98 participants; <a href="./references#CD003277-fig-0077" title="">Analysis 8.1</a>). We downgraded the certainty of evidence for this outcome twice for imprecision (from high to low) because the effect estimate has a very wide CI (<a href="./full#CD003277-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD003277-sec-0150"> <h5 class="title">Number of participants free from major seizures (drop attacks and tonic‐clonic seizures)</h5> <p>The RR was 4.08 (95% CI 1.46 to 11.39) in favour of the topiramate regimen (one study; 96 participants; <a href="./references#CD003277-fig-0078" title="">Analysis 8.2</a>). </p> </section> <section id="CD003277-sec-0151"> <h5 class="title">Number of participants with ≥ 75% reduction in major seizures (drop attacks and tonic‐clonic seizures) </h5> <p>The RR was 4.35 (95% CI 0.97 to 19.42) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 96 participants; <a href="./references#CD003277-fig-0079" title="">Analysis 8.3</a>). </p> </section> <section id="CD003277-sec-0152"> <h5 class="title">Number of participants with ≥ 50% reduction in major seizures (drop attacks and tonic‐clonic seizures) </h5> <p>The RR was 4.08 (95% CI 1.46 to 11.39) in favour of the topiramate regimen (one study; 96 participants; <a href="./references#CD003277-fig-0080" title="">Analysis 8.4</a>). </p> </section> <section id="CD003277-sec-0153"> <h5 class="title">Number of participants free from drop attacks</h5> <p>The Peto OR was 8.06 (99% CI 0.05 to 1398.41) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 96 participants; <a href="./references#CD003277-fig-0081" title="">Analysis 8.5</a>. </p> </section> <section id="CD003277-sec-0154"> <h5 class="title">Number of participants with ≥ 75% reduction in drop attacks</h5> <p>The RR was 2.84 (95% CI 0.80 to 10.06) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 95 participants; <a href="./references#CD003277-fig-0082" title="">Analysis 8.6</a>). </p> </section> <section id="CD003277-sec-0155"> <h5 class="title">Number of participants with ≥ 50% reduction in drop attacks</h5> <p>The RR was 1.98 (95% CI 0.87 to 4.52) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 95 participants; <a href="./references#CD003277-fig-0083" title="">Analysis 8.7</a>). </p> </section> <section id="CD003277-sec-0156"> <h5 class="title">Number of participants free from drop attacks during the maintenance phase</h5> <p>The RR was 1.33 (95% CI 0.38 to 4.66) in favour of the topiramate regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 95 participants; <a href="./references#CD003277-fig-0084" title="">Analysis 8.8</a>). </p> </section> <section id="CD003277-sec-0157"> <h5 class="title">Number of participants with severe adverse events</h5> <p>The RR was 2.29 (95% CI 0.86 to 6.11) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 98 participants; <a href="./references#CD003277-fig-0085" title="">Analysis 8.9</a>). </p> </section> <section id="CD003277-sec-0158"> <h5 class="title">Number of participants with adverse events leading to dose reduction or temporary discontinuation </h5> <p>The RR was 3.13 (95% CI 0.90 to 10.85) in favour of the placebo regimen but the CI included the possibility of an effect favouring either treatment regimen (one study; 98 participants; <a href="./references#CD003277-fig-0086" title="">Analysis 8.10</a>). </p> </section> <section id="CD003277-sec-0159"> <h5 class="title">Number of participants with adverse events leading to study discontinuation</h5> <p>No adverse events led to study discontinuation (one study; 98 participants; <a href="./references#CD003277-fig-0087" title="">Analysis 8.11</a>). We downgraded the certainty of the evidence twice for imprecision (from high to low) because the study was not powered to detect a between‐group difference in zero event outcomes (<a href="./full#CD003277-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD003277-sec-0160"> <h5 class="title">Death</h5> <p>No deaths were reported in the study.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003277-sec-0161" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003277-sec-0161"></div> <p>LGS is a complex and severe developmental and epileptic encephalopathy that manifests as multiple seizure types, which often evolve over time. Drop seizures (typically tonic, atonic or myoclonic‐atonic), is the characteristic seizure type. It is a syndrome that is difficult to treat, with many people receiving combination therapy (polypharmacy) but frequently without achieving seizure‐freedom. The aim of this review was to assess the efficacy and tolerability of anti‐seizure medications in the treatment of LGS. </p> <p>LGS is thought to account for up to 5% of all childhood epilepsies,yet we found only 11 RCTs for the pharmaceutical treatment of this syndrome. There are several possible explanations for this lack of evidence. LGS is primarily a syndrome of childhood; long‐term prognosis is expected to be poor with regard to the cognitive outcome, but seizures tend to become less troublesome into adulthood (<a href="./references#CD003277-bbs2-0047" title="FerlazzoE , NikanorovaM , ItalianoD , Bureau M, DravetC , CalareseT , et al. Lennox-Gastaut syndrome in adulthood: clinical and EEG features. Epilepsy Research2010;89(2-3):271-7. [PMID: 20149600]">Ferlazzo 2010</a>; <a href="./references#CD003277-bbs2-0070" title="VignoliA , OggioniG , De MariaG , PeronA , SaviniMN , ZambrelliE , et al. Lennox-Gastaut syndrome in adulthood: long-term clinical follow-up of 38 patients and analysis of their recorded seizures. Epilepsy &amp; Behavior2017;77:73-8. [PMID: 29126048]">Vignoli 2017</a>). Preferably, drug treatments would be evaluated earlier in the course of the condition, closer to seizure onset. There has traditionally been reluctance to set up trials in the paediatric age group as it is both difficult and expensive, and continues to be so, despite the early exclusivity clause set out by EU Regulations (<a href="./references#CD003277-bbs2-0046" title="The European Parliament and the Council of the European Union. Regulation (EC) No 1901/2006 of the European Council and of the Council of 12th December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. www.emea.europa.eu/htms/human/paediatrics/regulation.htm2006.">European Union 2006</a>). Due to the low incidence of LGS (two cases per 100,000 children), a multicentre collaborative study design to enrol the numbers of individuals is required for sufficient power with consensus on the selection of individuals (diagnostic criteria), drug therapy, and outcome measures (<a href="./references#CD003277-bbs2-0031" title="ArzimanoglouA , FrenchJ , BlumeWT , CrossJ , ErnstJP , FeuchtM , et al. Lennox Gastaut syndrome: a consensus approach on diagnosis, assessment, management and trial methodology. Lancet Neurology2009;8(1):82-93. [PMID: 19081517]">Arzimanoglou 2009</a>). Investigation of adjunctive and especially monotherapy ASM regimens is difficult because LGS characteristics usually evolve over time, including multiple seizure types and typical EEG appearances. As such, many individuals will have already received several ASMs at diagnosis. The natural history of the syndrome shows that the frequency and type of seizures often fluctuate over time, which means the observed improvement or deterioration might not be an effect of the study intervention. Most challenging is the adequate observation and reporting of seizure types with more subtle clinical manifestations, such as atypical absence and myoclonic seizures. This variation may account for the heterogeneous seizure outcome measures applied across the studies included in this review. Some more recent RCTs use pragmatic 'seizure definitions', such as drop seizures with motor manifestations resulting in loss of posture (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a>; <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a>; <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>); this approach might be more quantifiable and have more clinical impact. Studies included in this review have applied different seizure outcome measures, with more recent studies focusing on drop seizures, a seizure type that is measurable and is expected to have the most negative clinical impact. Observation and recording of the different seizure types, in particular, those with more subtle clinical manifestations, such as atypical absence and myoclonic seizures, is challenging for carers of participating patients. This factor may be one reason for the variation in seizure outcome measures applied across studies in this review. Furthermore, LGS is an aetiologically heterogeneous condition, and the different aetiologies of LGS could affect the effectiveness outcomes of the different ASMs. For example, selected patients with an underlying monogenetic disorder such as a SCN2A mutation (resulting in gain or loss of sodium channel function) and LGS phenotype and may respond differently to sodium channel‐blocking ASMs (<a href="./references#CD003277-bbs2-0039" title="BrunklausA , DuJ , StecklerF , GhantyII , JohannesenKM , FengerCD , et al. Biological concepts in human sodium channel epilepsies and their relevance in clinical practice. Epilepsia2020;61(3):387-99. [DOI: 10.1111/epi.16438]">Brunklaus 2020</a>; <a href="./references#CD003277-bbs2-0072" title="WolffM , JohannesenKM , HedrichUBS , MasnadaS , RubboliG , GardellaE , et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain2017;140(5):1316-36. [DOI: 10.1093/brain/awx054] [PMID: 28379373]">Wolff 2017</a>). </p> <p>We found only one trial that included behaviour as a primary outcome domain, even though behaviour and cognition are frequently cited by families as being the most difficult features of the syndrome to accept and manage. The primary focus of most trials of ASMs is on seizure control and it is expected that other types of medications would be indicated for modifying cognitive and behavioural function rather than ASMs. </p> <p>Recent clinical practice guidelines have recommended the use of some ASMs for the treatment of LGS. The 2004 guidelines of the American Academy of Neurology and American Epilepsy Society for pharmacological management of treatment‐resistant epilepsy (<a href="./references#CD003277-bbs2-0048" title="FrenchJA , KannerAM , BautistaJ , Abou-KhalilB , BrowneT , HardenCL , et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology2004;62(8):1252-60. [PMID: 15111659]">French 2004</a>) found felbamate, lamotrigine, and topiramate to be effective ASMs in treating LGS. The 2018 update of these guidelines (<a href="./references#CD003277-bbs2-0055" title="KannerAM , AshmanE , GlossD , HardenC , BourgeoisB , BautistaJF , et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology2018;91(2):82-90. [PMID: 29898974]">Kanner 2018</a>) listed also rufinamide as an established treatment, reporting that clobazam should be considered to decrease seizure frequency. According to the 2012 National Institute for Health and Care Excellence (NICE) guidelines (<a href="./references#CD003277-bbs2-0059" title="National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. Clinical guideline [CG137]. Available from: https://www.nice.org.uk/guidance/cg137 (accessed 19/02/2021) 11 January 2012.">NICE 2012</a>), add‐on ASMs that may be considered for children, young people and adults with LGS are rufinamide and topiramate; if they are ineffective or not tolerated, felbamate can be offered. Carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin should be avoided. According to a 2019 NICE technology appraisal guidance (<a href="./references#CD003277-bbs2-0060" title="National Institute for Health and Care Excellence (NICE). Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome. Technology appraisal guidance [TA615]. Available from: https://www.nice.org.uk/guidance/ta615 (accessed 19/02/2021) 18 December 2019.">NICE 2019</a>), cannabidiol with clobazam is recommended as an option for patients aged two years and older with LGS, if their drop seizures are not controlled after 2 or more ASMS, and provided that "the frequency of drop seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment." </p> <section id="CD003277-sec-0162"> <h3 class="title" id="CD003277-sec-0162">Summary of main results</h3> <p>We found that the evidence for drug treatment of LGS related specifically to the use of anti‐seizure medications. Some of the included studies involved the treatment of children only, and others involved both children and adults with LGS. All 11 included trials (1277 participants) used ASMs as add‐on therapy and had variable periods of dose adjustment and maintenance; we found no trials of ASMs used as monotherapy and no head‐to‐head comparisons of specific add‐on drugs. We identified one trial registry record for a study that planned to compare add‐on rufinamide with lamotrigine but the study was reported to have been terminated because those supporting the study did not want to proceed with marketing the product. </p> <p>Three included RCTs reported outcomes for both overall seizure reduction and adverse events leading to study discontinuation. We found high‐certainty evidence that add‐on lamotrigine increased the number of participants with at least 50% reduction in the average number of reported seizures and low‐certainty evidence that add‐on lamotrigine may have reduced the number of participants with adverse events leading to study discontinuation when compared to add‐on placebo. We also found high‐certainty evidence that add‐on rufinamide increased the number of participants with at least 50% reduction in the average number of reported seizures when compared with add‐on placebo and low‐certainty evidence that add‐on rufinamide may have made little or no difference compared to add‐on placebo or another unspecified ASM in terms of reducing the number of participants with adverse events leading to study discontinuation. Add‐on topiramate may have increased the number of participants with at least 75% reduction in the average number of reported seizures, and probably made little or no difference to the number of adverse events leading to study discontinuation when compared to add‐on placebo (low‐certainty evidence). Add‐on felbamate (treatment phase) may have made little or no difference in terms of complete seizure freedom and adverse events leading to study discontinuation when compared to add‐on placebo (low certainty evidence). However, we found that when seizures were recorded under EEG monitoring, add‐on felbamate may have increased seizure freedom compared to add‐on placebo. We remain uncertain whether other add‐on drug therapies, including cannabidiol, cinromide and clobazam, reduced all types of seizures because this outcome was not reported or had very low‐certainty evidence. Despite therapeutic potential for reducing drop seizures, we found high‐certainty evidence that add‐on cannabidiol and add‐on clobazam increased the number of participants with adverse events leading to study discontinuation compared to add‐on placebo. We did not find any evidence for adverse events leading to study discontinuation in the comparison of add‐on cinromide with add‐on placebo. </p> <p>There were insufficient data to perform subgroup analysis for the pre‐specified variables, dosage, timing, and length of treatment. Most of the evidence included in this review related to people from middle‐ or high‐income countries and, where reported, participants of white ethnicity. </p> </section> <section id="CD003277-sec-0163"> <h3 class="title" id="CD003277-sec-0163">Overall completeness and applicability of evidence</h3> <p>We excluded three studies on the basis that data were not usable. However, we did not attempt to obtain additional data from the authors because the studies were published more than 25 years ago. We acknowledge this as a limitation of the review. In addition, we listed one potentially relevant study as awaiting classification in the absence of a translation into English. We also acknowledge this as a limitation of the review. </p> <p>All included trials used ASMs as add‐on therapy. Hence, the data on the treatment of LGS from RCTs refer to ASMs given as adjunctive treatments. The earliest trial of an add‐on therapy, cinromide, is not currently used in clinical practice and evidence relates only to patients up to the age of 18 years. We found limited reporting of outcomes for cognition and behaviour. We also found that some of the more recent studies focused on drop seizure reduction as a primary outcome. Our 'Summary of findings' tables focused on overall seizure cessation, reduction and adverse events in accordance with the previous version of this review and because multiple types of seizures are reported in LGS. </p> </section> <section id="CD003277-sec-0164"> <h3 class="title" id="CD003277-sec-0164">Quality of the evidence</h3> <p>For outcomes included in the Summary of Findings table, we found the certainty of evidence to be of moderate‐ to very low‐certainty. We primarily downgraded outcomes because the evidence was not powered to detect a between‐group difference (study limitations). We also downgraded outcomes due to imprecise estimates with wide or very wide CIs. In addition, we downgraded outcomes from one study that was judged to have a very serious risk of bias due to attrition and selective reporting (<a href="./references#CD003277-bbs2-0006" title="Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia1989;30(4):422-9. [PMID: 2666120]">Group for the Evaluation of Cinromide 1989</a>). </p> </section> <section id="CD003277-sec-0165"> <h3 class="title" id="CD003277-sec-0165">Potential biases in the review process</h3> <p>We made every effort to identify all RCTs on the use of ASMs for LGS through a comprehensive search of the literature, and it is unlikely that we failed to identify large relevant studies. However, despite our efforts, there remains the possibility that we have missed small studies published in the less accessible literature. We also contacted drug companies and experts in the field to obtain information on ongoing trials or unpublished results. Finally, we contacted authors of one included study, published in 2019, to obtain information on missing data, and we contacted trialists to determine the completion of another study. We acknowledge a potential bias in our review process because we did not attempt to contact all study authors for additional data. Unavoidably, some of the authors of this review were familiar with most of the included trials before updating this review. However, data extraction was undertaken blind to the results of the prior version of the review. </p> </section> <section id="CD003277-sec-0166"> <h3 class="title" id="CD003277-sec-0166">Agreements and disagreements with other studies or reviews</h3> <p>We identified a narrative review of drug therapies for LGS that concluded a lack of evidence of the efficacy of any one drug over another. The review reported that drug therapies are difficult to compare even in RCTs, and suggested that non‐medical therapies may be considered after the failure of two to three drugs (<a href="./references#CD003277-bbs2-0037" title="BorrelliS , El TahryR . Therapeutic approach to Lennox-Gastaut syndrome: a systematic review. Acta Neurololgica Belgica2019;119(3):315-24. [PMID: 31286465]">Borrelli 2019</a>). We found some evidence in favour of the use of add‐on lamotrigine compared with add‐on placebo in terms of both overall reduction in average reported seizures and adverse events leading to study discontinuation. However, we also found a lack of RCTs assessing the therapeutic potential of monotherapy and head‐to‐head comparison of specific add‐on ASMs. It is beyond the scope of this review to make recommendations on the use of non‐medical therapies for LGS. </p> <p>We identified several reviews of individual add‐on ASMs for the treatment of LGS. In 2018, a meta‐analysis of add‐on cannabidiol versus add‐on placebo was performed, based on two studies included in this review (<a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> and <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>). In addition to the assessment of different types of seizures, this meta‐analysis also included data for all seizure frequency. The review authors reported that "rates of &gt; 50% reduction of all seizures were also higher among patients randomised to the active drug rather than placebo (37.2% vs 21.2%; RR 1.76 (95% CI 1.07‐2.88); P = 0.025)" (<a href="./references#CD003277-bbs2-0056" title="LattanziS , BrigoF , CagnettiC , TrinkaE , SilvestriniM . Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs2018;32(10):905-16. [DOI: 10.1007/s40263-018-0558-9] [PMID: 30132269]">Lattanzi 2018</a>). However, we did not find outcome data reported for greater than 50% reduction in all seizures in <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> or <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a>; these data were not included in our analysis of the evidence. </p> <p>Previously, an indirect comparison was undertaken of add‐on felbamate, lamotrigine, topiramate, rufinamide and clobazam (<a href="./references#CD003277-bbs2-0041" title="CramerJA , SapinC , FrançoisC . Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurologica Scandinavica2013;128(2):91-9. [DOI: 10.1111/ane.12086] [PMID: 23410109]">Cramer 2013</a>). Although the authors found some evidence in favour of add‐on clobazam, they acknowledged several limitations including overlapping 95% CIs, omission of adverse event outcomes and studies often using dose ranges rather than a specific dosage. The authors of this analysis were also employed by the manufacturer of clobazam. We did not identify publication bias in the included studies in this review but we did find that some study investigators declared financial interests in their study sponsor. </p> <p>In 2010, one study evaluated the cost effectiveness of rufinamide in the treatment of LGS. Based on data from the UK, this study concluded that, for managing drop seizures, "if society is willing to pay an additional £250 or more for a 1% increase in patients achieving at least a 50% reduction in seizure frequency over 3 years, rufinamide has more than an 80% probability of being cost effective compared with either lamotrigine or topiramate" (<a href="./references#CD003277-bbs2-0034" title="BenedictA , VerdianL , MaclaineG . The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics2010;28(3):185-99 [Erratum in: Pharmacoeconomics 2011;29(12):1014]. [DOI: 10.2165/11313640-000000000-00000] [PMID: 20151724]">Benedict 2010</a>). We did not assess cost‐effectiveness in this review, but recognise a need for up‐to‐date modelling to help inform decision‐making. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003277-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003277-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003277-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from drop seizures during the treatment phase" data-id="CD003277-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75% reduction in drop seizures during the treatment phase" data-id="CD003277-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75% reduction in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in drop seizures during the treatment phase" data-id="CD003277-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25 % reduction in drop seizures during the treatment phase" data-id="CD003277-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25 % reduction in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 5: Number of participants with &gt; 0% to &lt; 25% reduction in drop seizures during the treatment phase" data-id="CD003277-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 5: Number of participants with &gt; 0% to &lt; 25% reduction in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 6: Number of participants with &gt; 0% to &lt; 25% increase in drop seizures during the treatment phase" data-id="CD003277-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 6: Number of participants with &gt; 0% to &lt; 25% increase in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 7: Number of participants with &gt; 25 % increase in drop seizures during the treatment phase" data-id="CD003277-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 7: Number of participants with &gt; 25 % increase in drop seizures during the treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 8: Number of participants with improvement in the patient and caregiver Global Impression of Care scale" data-id="CD003277-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 8: Number of participants with improvement in the patient and caregiver Global Impression of Care scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 9: Number of participants free from drop seizures during the maintenance phase" data-id="CD003277-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 9: Number of participants free from drop seizures during the maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 10: Number of participants with ≥ 75% reduction in drop seizures during the maintenance phase" data-id="CD003277-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 10: Number of participants with ≥ 75% reduction in drop seizures during the maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 11: Number of participants with ≥ 50% reduction in drop seizures during the maintenance phase" data-id="CD003277-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 11: Number of participants with ≥ 50% reduction in drop seizures during the maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 12: Number of participants with ≥ 25 % reduction in drop seizures during the maintenance phase" data-id="CD003277-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 12: Number of participants with ≥ 25 % reduction in drop seizures during the maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 13: Number of participants with adverse events" data-id="CD003277-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 13: Number of participants with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 14: Number of participants with treatment‐related adverse events" data-id="CD003277-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 14: Number of participants with treatment‐related adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 15: Number of participants with serious adverse events" data-id="CD003277-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 15: Number of participants with serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 16: Number of participants with adverse events leading to dose reduction" data-id="CD003277-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 16: Number of participants with adverse events leading to dose reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 17: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 17: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 18: Death" data-id="CD003277-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs, Outcome 18: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from all seizures" data-id="CD003277-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75% reduction in mean weekly seizures" data-id="CD003277-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75% reduction in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in mean weekly seizures" data-id="CD003277-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25% reduction in mean weekly seizures" data-id="CD003277-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25% reduction in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 5: Number of participants with ≥ 0% to &lt; 25% reduction in mean weekly seizures" data-id="CD003277-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 5: Number of participants with ≥ 0% to &lt; 25% reduction in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 6: Number of participants with ≥ 0% to &lt; 25% increase in mean weekly seizures" data-id="CD003277-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 6: Number of participants with ≥ 0% to &lt; 25% increase in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 7: Number of participants with &gt; 25% increase in mean weekly seizures" data-id="CD003277-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 7: Number of participants with &gt; 25% increase in mean weekly seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 8: Number of participants with improvement in global evaluation" data-id="CD003277-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 8: Number of participants with improvement in global evaluation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 9: Number of participants with no change in global evaluation" data-id="CD003277-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 9: Number of participants with no change in global evaluation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 10: Number of participants with worsening in global evaluation" data-id="CD003277-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 10: Number of participants with worsening in global evaluation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 11: Number of participants with worsening in global evaluation ‐ Week 24" data-id="CD003277-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Cinromide + ASMs versus placebo + ASMs, Outcome 11: Number of participants with worsening in global evaluation ‐ Week 24 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from drop seizures" data-id="CD003277-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from drop seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate)" data-id="CD003277-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate)" data-id="CD003277-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate)" data-id="CD003277-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 5: Number of participants with adverse events" data-id="CD003277-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 5: Number of participants with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 6: Number of participants with adverse events leading to dose reduction" data-id="CD003277-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 6: Number of participants with adverse events leading to dose reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 7: Number of participants with aggression‐related adverse events" data-id="CD003277-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 7: Number of participants with aggression‐related adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 8: Number of participants with serious adverse events" data-id="CD003277-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 8: Number of participants with serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 9: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 9: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 10: Death" data-id="CD003277-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs, Outcome 10: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography)" data-id="CD003277-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 1: Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 2: Number of participants free from all seizures ‐ Treatment phase" data-id="CD003277-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 2: Number of participants free from all seizures ‐ Treatment phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 3: Number of participants free from all seizures ‐ Maintenance phase" data-id="CD003277-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 3: Number of participants free from all seizures ‐ Maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 4: Number of participants free from atonic seizures" data-id="CD003277-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 4: Number of participants free from atonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 5: Number of participants free from tonic‐clonic seizures" data-id="CD003277-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 5: Number of participants free from tonic‐clonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 6: Number of participants with severe side effects" data-id="CD003277-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 6: Number of participants with severe side effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 7: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Felbamate + ASMs versus placebo + ASMs, Outcome 7: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥ 50% median reduction in all seizures" data-id="CD003277-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥ 50% median reduction in all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 2: Number of participants with &gt; 25% to &lt; 50% median reduction in all seizures" data-id="CD003277-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 2: Number of participants with &gt; 25% to &lt; 50% median reduction in all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 3: Number of participants with either 0 to ≤ 25% median reduction or an increase in all seizures" data-id="CD003277-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 3: Number of participants with either 0 to ≤ 25% median reduction or an increase in all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 50% median reduction in drop attacks" data-id="CD003277-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 50% median reduction in drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 5: Number of participants with &gt; 25% to &lt; 50% median reduction in drop attacks" data-id="CD003277-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 5: Number of participants with &gt; 25% to &lt; 50% median reduction in drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 6: Number of participants with either ≤ 25% median reduction or an increase in the number of drop attacks" data-id="CD003277-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 6: Number of participants with either ≤ 25% median reduction or an increase in the number of drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 7: Number of participants with ≥ 50% median reduction in tonic‐clonic seizures" data-id="CD003277-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 7: Number of participants with ≥ 50% median reduction in tonic‐clonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 8: Number of participants with &gt; 25% to &lt; 50% median reduction in tonic‐clonic seizures" data-id="CD003277-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 8: Number of participants with &gt; 25% to &lt; 50% median reduction in tonic‐clonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 9: Number of participants with 0 to ≤ 25% median reduction or an increase in the number of tonic‐clonic seizures" data-id="CD003277-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 9: Number of participants with 0 to ≤ 25% median reduction or an increase in the number of tonic‐clonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 10: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Lamotrigine + ASMs versus placebo + ASMs, Outcome 10: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥ 50% reduction in all seizures" data-id="CD003277-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥ 50% reduction in all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75 % reduction in tonic‐atonic seizures" data-id="CD003277-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 2: Number of participants with ≥ 75 % reduction in tonic‐atonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in tonic‐atonic seizures" data-id="CD003277-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 50% reduction in tonic‐atonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25% reduction in tonic‐atonic seizures" data-id="CD003277-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 25% reduction in tonic‐atonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 5: Number of participants 'unchanged' (&lt; 25% reduction in tonic‐atonic seizures)" data-id="CD003277-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 5: Number of participants 'unchanged' (&lt; 25% reduction in tonic‐atonic seizures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 6: Number of participants with increased tonic‐atonic seizures" data-id="CD003277-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 6: Number of participants with increased tonic‐atonic seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 7: Number of participants with improvement in seizure severity rating" data-id="CD003277-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 7: Number of participants with improvement in seizure severity rating </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 8: Number of participants with adverse events" data-id="CD003277-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 8: Number of participants with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 9: Number of participants with adverse events suspected to be treatment‐related" data-id="CD003277-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 9: Number of participants with adverse events suspected to be treatment‐related </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 10: Number of participants with serious adverse events" data-id="CD003277-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 10: Number of participants with serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 11: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Rufinamide + ASMs versus placebo + ASMs, Outcome 11: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 1: Number of participants with treatment‐emergent adverse events" data-id="CD003277-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 1: Number of participants with treatment‐emergent adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 2: Number of participants with severe treatment‐emergent adverse events" data-id="CD003277-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 2: Number of participants with severe treatment‐emergent adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 3: Number of participants with serious treatment‐emergent adverse events" data-id="CD003277-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 3: Number of participants with serious treatment‐emergent adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 4: Number of participants with treatment‐emergent adverse events leading to study‐drug dose adjustment" data-id="CD003277-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 4: Number of participants with treatment‐emergent adverse events leading to study‐drug dose adjustment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 5: Number of participants with treatment‐emergent adverse events leading to study discontinuation" data-id="CD003277-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 5: Number of participants with treatment‐emergent adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 6: Death" data-id="CD003277-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 6: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 7: Child Behaviour Checklist Questionnaire" data-id="CD003277-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Rufinamide + ASMs versus other ASM + ASMs, Outcome 7: Child Behaviour Checklist Questionnaire </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥75% reduction in all seizures" data-id="CD003277-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 1: Number of participants with ≥75% reduction in all seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 2: Number of participants free from major seizures (drop attacks and tonic‐clonic seizures)" data-id="CD003277-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 2: Number of participants free from major seizures (drop attacks and tonic‐clonic seizures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 75% reduction in major seizures (drop attacks and tonic‐clonic seizures)" data-id="CD003277-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 3: Number of participants with ≥ 75% reduction in major seizures (drop attacks and tonic‐clonic seizures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 50% reduction in major seizures (drop attacks and tonic‐clonic seizures)" data-id="CD003277-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 4: Number of participants with ≥ 50% reduction in major seizures (drop attacks and tonic‐clonic seizures) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 5: Number of participants free from drop attacks" data-id="CD003277-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 5: Number of participants free from drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 6: Number of participants with ≥ 75% reduction in drop attacks" data-id="CD003277-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 6: Number of participants with ≥ 75% reduction in drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 7: Number of participants with ≥ 50% reduction in drop attacks" data-id="CD003277-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 7: Number of participants with ≥ 50% reduction in drop attacks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 8: Number of participants free from drop attacks during the maintenance phase" data-id="CD003277-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 8: Number of participants free from drop attacks during the maintenance phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 9: Number of participants with severe adverse events" data-id="CD003277-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 9: Number of participants with severe adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 10: Number of participants with adverse events leading to dose reduction or temporary discontinuation" data-id="CD003277-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 10: Number of participants with adverse events leading to dose reduction or temporary discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003277-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/urn:x-wiley:14651858:media:CD003277:CD003277-CMP-008.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 11: Number of participants with adverse events leading to study discontinuation" data-id="CD003277-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_t/tCD003277-CMP-008.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8: Topiramate + ASMs versus placebo + ASMs, Outcome 11: Number of participants with adverse events leading to study discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/media/CDSR/CD003277/image_n/nCD003277-CMP-008.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries<br/><b>Intervention:</b> cannabidiol (10mg/kg and 20mg/kg) + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cannabidiol + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures follow up: after 14 weeks' treatment (titration and maintenance) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. No participants were free from drop seizures (one study; 225 participants) <a href="./references#CD003277-fig-0003" title="">Analysis 1.1</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 14 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants with ≥ 75% reduction in drop seizures: RR 3.51 (95% CI 1.24 to 9.92) in favour of the cannabidiol regimen (two studies; 396 participants) <a href="./references#CD003277-fig-0004" title="">Analysis 1.2</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 14 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants with ≥ 50% reduction in drop seizures: RR 2.12 (95% CI 1.48 to 3.03) in favour of the cannabidiol regimen (two studies; 396 participants; <a href="./references#CD003277-fig-0005" title="">Analysis 1.3</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 19 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.62<br/>(1.56 to 28.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention in <a href="./references#CD003277-bbs2-0002" title="DevinskyO , PatelAD , CrossJH , VillanuevaV , WirrellEC , PriviteraM , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine2018;378(20):1888-97. [DOI: 10.1056/NEJMoa1714631] [PMID: 29768152]PatelA , DevinskyO , CrossJH , VillanuevaV , WirrellE , VanLandinghamK , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3). Neurology2017;89(8):e100. [DOI: 10.1212/wnl.0000000000004380]WirrellE , DevinskyO , PatelA , ZuberiS , CrossJ , VillanuevaV , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3). Annals of Neurology2017;82(S21):S279-80, Abstract no: 22. ZuberiS , DevinskyO , PatelA , CrossJH , VillanuevaV , WirrellEC , et al. Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3). Epilepsia2017;58(Suppl 5):S13-4, Abstract no: 0026. [DOI: 10.1111/epi.13944]">Devinsky 2018</a> involved two doses of cannabidiol (10 mg/kg and 20 mg/kg); 6 of the 7 adverse events leading to study discontinuation occurred in the higher dose group; intervention in <a href="./references#CD003277-bbs2-0011" title="FrenchJ , ThieleE , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshE , JoshiC , et al. Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4). Neurology2017;88(16 Suppl):Abstract no: S21.001. JoshiC , ThieleE , MarshE , FrenchJ . Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4). Annals of Neurology2017;82(S21):S293, Abstract no: 42. Mazurkiewicz-BeldzinskaM , ThieleEA , BenbadisS , MarshED , JoshiC , FrenchJA , et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4). Epilepsia2017;58(Suppl 5):S55, Abstract no: p0238. [DOI: 10.1111/epi.13944]ThieleEA , MarshED , FrenchJA , Mazurkiewicz-BeldzinskaM , BenbadisSR , JoshiC , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2018;391(10125):1085-96. [PMID: 29395273]ThieleEA , Mazurkiewicz-BeldzinskaM , BenbadisS , MarshED , JoshiC , French JA et al. Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). Neurotherapeutics2017;14(3):824-5. [DOI: 10.1007/s13311-017-0543-x]">Thiele 2018</a> also involved the higher dose of cannabidiol (20 mg/kg). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(19 to 350) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cinromide plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cinromide + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<sup>1</sup><br/><b>Setting:</b> USA<br/><b>Intervention:</b> cinromide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with cinromide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 75% reduction in mean weekly seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 9.35<br/>(0.45 to 194.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cinromide + ASMs: 3/26 participants;</p> <p>placebo + ASMs: 0/30 participants.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% reduction in mean weekly seizures<br/>follow‐up: after 18 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/>(0.47 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>2,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/>(110 to 667) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with adverse events leading to study discontinuation</p> <p>follow‐up: after 18 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>Peto</b> <b>OR:</b> Peto<b>o</b>dds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>The evidence for this comparison included children and adolescents only. </p> <p><sup>2</sup>Downgraded twice for study limitations because there was a high risk of bias from incomplete data (study terminated prematurely). </p> <p><sup>3</sup>Downgraded twice for imprecision because the study was not powered to detect a between‐group difference in zero event outcomes. </p> <p><sup>4</sup>Downgraded twice for imprecision because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cinromide plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clobazam (low, medium and high doses) plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clobazam (low, medium and high doses) + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries and one middle‐income country<br/><b>Intervention:</b> clobazam (low, medium and high doses) + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with clobazam + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome. Number of participants free from drop seizures: RR 4.10 (95% CI 1.00 to 16.83) in favour of the clobazam regimen (1 study; 217 participants) <a href="./references#CD003277-fig-0032" title="">Analysis 3.1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: "from the 4‐week baseline period to the 12‐week maintenance period" (with 3 weeks titration) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: 22 weeks (after baseline, titration, maintenance and tapering) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.12<br/>(1.01 to 16.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention in <a href="./references#CD003277-bbs2-0008" title="ChungSS , GidalBE , LemmingOM , Karnik-HenryM , HacklerE , Tolbert D et al. Combination AED treatment with clobazam in patients with Lennox–Gastaut syndrome: post hoc analyses of the CONTAIN study. Neurology2018;90(15 Suppl):Abstract no: P4.264. ConryJ , NgY , CollinsS , BradtJ , StolleJ , TracyK , et al. Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome. Epilepsia2007;48(Suppl 6):360-1, Abstract no: 3.305. ConryJ , NgY , DrummondR , StolleJ , SagarS . Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial. In: 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX. www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/clobazam/sy/2010/sb/All/id/, (accessed 28 April 2012):Abstract no: 1.283. ConryJ , NgYT , PengG , LeeD , IsojarviJ . Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):391-2, Abstract no: 3.204. ConryJA , NgYT , DrummondR , StolleJ , OwenJR , WeinbergMA . Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study. Annals of Neurology2011;70(S15):S113, Abstract no: 14. [DOI: 10.1002/ana.22572]IsojarviJ , LeeD , PengG , SperlingMR . Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. Epilepsia2016;57(6):e113-6. [DOI: 10.1111/epi.13388] [PMID: 27145465]IsojarviJ , LeeD , RenfroeJB . Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS). Annals of Neurology2013;74(Suppl 17):S75, Abstract no: M2224. [DOI: 10.1002/ana.24068]IsojarviJ , LeeD . Response to clobazam in relationship to baseline seizure frequency. Neurology2013;80(7 Suppl):Abstract no: P07.176. LeeD , RosenfeldW , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam. Annals of Neurology2013;74(Suppl 17):S72, Abstract no. M2211. [DOI: http://dx.doi.org/10.1002/ana.24068]NgYT , ConryJA , DrummondR , StolleJ , WeinbergMA , OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology2011;77(15):1473-81. [DOI: 10.1212/WNL.0b013e318232de76] [PMID: 21956725]PaolicchiJ , IsojarviJ , LeeD . Aggression in LGS patients treated with clobazam during the CONTAIN trial. Epilepsy Currents2013;13(Suppl 1):266-7, Abstract no: 2.13. PaolicchiJM , RossG , LeeD , DrummondR , IsojarviJ . Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome. Pediatric Neurology2015;53(4):338-42. [PMID: 26245776]RosenfeldW , IsojarviJ , NicholK , LeeD . Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial. Epilepsy Currents2014;14(Suppl 1):392, Abstract no: 3.205. RosenfeldW , LeeD , IsojarviJ . Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial. Neurology2013;80(7 Suppl):Abstract no: P01.046. ">Ng 2011</a> involved three doses of clobazam (low, medium, high) and study authors state that "A dosage related trend was observed for the overall incidence of [adverse events] leading to discontinuation." </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000<br/>(34 to 572) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clobazam (low, medium and high doses) plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Felbamate plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Felbamate + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> USA<br/><b>Intervention:</b> felbamate + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with felbamate + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) ‐<br/>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.92<br/>(0.32 to 26.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(9 to 744) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants free from all seizures<br/>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after the treatment phase, which "consisted of a 14‐day titration period and a 56‐day maintenance period" </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to a retrospective analysis "Approximately 50% of patients randomised to FBM obtained at least a 50% reduction in seizure frequency compared with about 15% receiving placebo." </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow up: after 14 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/>(0.06 to 14.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(2 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval;<b>FBM:</b> felbamate; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice for imprecision because the effect estimate has a very wide confidence interval. </p> <p><sup>2</sup>Downgraded twice for imprecision because the study was not powered to detect a between‐group difference in zero event outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Felbamate plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lamotrigine plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre<br/><b>Intervention:</b> lamotrigine + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 16 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 16 weeks' treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% median reduction in all seizures<br/>follow‐up: after 16 weeks' treatment </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/>(1.19 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>167<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(187 to 591) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 20 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49<br/>(0.13 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>169<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(10 to 142) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Lamotrigine plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Rufinamide plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rufinamide + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries and one middle‐income country<br/><b>Intervention:</b> rufinamide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with rufinamide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 50% reduction in all seizures<br/>follow‐up: after 84 days/12 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.84<br/>(1.31 to 6.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>138<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(143 to 676) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with adverse events leading to study discontinuation</p> <p>follow‐up: after 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>138 per 1000</p> <p>(16 to 1,000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.14 (0.49 to 34.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Rufinamide plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rufinamide plus ASMs compared to other ASM plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rufinamide + ASMs compared to other ASM + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, high‐income countries<br/><b>Intervention:</b> rufinamide + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with rufinamide + ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 75% reduction in all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 106 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with treatment‐emergent adverse events leading to study discontinuation<br/>follow‐up: after 112 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.10 to 9.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/>(8 to 798) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rufinamide plus ASMs compared to other ASM plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003277-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Topiramate plus ASMs compared to placebo plus ASMs</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topiramate + ASMs compared to placebo + ASMs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Lennox‐Gastaut syndrome, any age<br/><b>Setting:</b> multi‐centre, USA<br/><b>Intervention:</b> topiramate + ASMs<br/><b>Comparison:</b> placebo + ASMs </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo + ASMs</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Topiramate+ ASMs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants free from all seizures</p> <p>follow‐up: after 11 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with ≥ 75% reduction in all seizures<br/>follow‐up: after 11 weeks' treatment (titration and maintenance) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Peto OR 8.22<br/>(0.60 to 112.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Topiramate + ASMs: 4/48 participants;</p> <p>placebo + ASMs: 0/50 participants.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants with ≥ 50% reduction in all seizures</p> <p>follow‐up: after 11 weeks' treatment (titration and maintenance)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events leading to study discontinuation<br/>follow‐up: after 11 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>98<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ASM:</b> anti‐seizure medication; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice because the effect estimate has a very wide confidence interval. </p> <p><sup>2</sup>Downgraded twice because the study was not powered to detect a between‐group difference in zero event outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Topiramate plus ASMs compared to placebo plus ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/full#CD003277-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of participants free from drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of participants with ≥ 75% reduction in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [1.24, 9.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of participants with ≥ 50% reduction in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.48, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Number of participants with ≥ 25 % reduction in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Number of participants with &gt; 0% to &lt; 25% reduction in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.85, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Number of participants with &gt; 0% to &lt; 25% increase in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.66, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Number of participants with &gt; 25 % increase in drop seizures during the treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.33, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Number of participants with improvement in the patient and caregiver Global Impression of Care scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.22, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Number of participants free from drop seizures during the maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.76 [0.75, 79.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Number of participants with ≥ 75% reduction in drop seizures during the maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.28, 6.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Number of participants with ≥ 50% reduction in drop seizures during the maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.25, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Number of participants with ≥ 25 % reduction in drop seizures during the maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.02, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.11, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Number of participants with treatment‐related adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.29, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Number of participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.94 [1.76, 13.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Number of participants with adverse events leading to dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.93 [0.73, 48.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.62 [1.56, 28.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [0.04, 1261.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cannabidiol (10 mg/kg and 20 mg/kg) + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cinromide + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Number of participants free from all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Number of participants with ≥ 75% reduction in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.35 [0.45, 194.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Number of participants with ≥ 50% reduction in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.47, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Number of participants with ≥ 25% reduction in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.59, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Number of participants with ≥ 0% to &lt; 25% reduction in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.42, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Number of participants with ≥ 0% to &lt; 25% increase in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.21, 3.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Number of participants with &gt; 25% increase in mean weekly seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.30, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Number of participants with improvement in global evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.56, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Week 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Week 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.62, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Number of participants with no change in global evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Week 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Week 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.46, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Number of participants with worsening in global evaluation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Week 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.46 [0.38, 31.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Week 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.62 [0.55, 38.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Number of participants with worsening in global evaluation ‐ Week 24 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.09 [0.17, 475.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cinromide + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Number of participants free from drop seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [1.00, 16.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Number of participants with ≥ 75 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [1.85, 8.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Number of participants with ≥ 50 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.26, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Number of participants with ≥ 25 % reduction in drop seizures (from baseline to maintenance phase in average weekly rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.17, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.97, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Number of participants with adverse events leading to dose reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.23 [1.28, 66.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Number of participants with aggression‐related adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.69, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Number of participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.54, 9.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.12 [1.01, 16.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Clobazam (low, medium and high doses) + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Felbamate + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Number of participants free from all seizures (recorded by closed‐circuit television and electroencephalography) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Treatment phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.32, 26.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Maintenance phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.84 [0.74, 46.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Number of participants free from all seizures ‐ Treatment phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Number of participants free from all seizures ‐ Maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.89 [0.46, 33.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Maintenance phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.89 [0.46, 33.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Number of participants free from atonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Treatment phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.43 [0.30, 137.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Maintenance phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.99 [0.62, 78.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Number of participants free from tonic‐clonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Treatment phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.17, 15.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Maintenance phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.69 [0.80, 40.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Number of participants with severe side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.75, 9.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 14.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Felbamate + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lamotrigine + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Number of participants with ≥ 50% median reduction in all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.19, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Number of participants with &gt; 25% to &lt; 50% median reduction in all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.80, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Number of participants with either 0 to ≤ 25% median reduction or an increase in all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Number of participants with ≥ 50% median reduction in drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.02, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Number of participants with &gt; 25% to &lt; 50% median reduction in drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.87, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Number of participants with either ≤ 25% median reduction or an increase in the number of drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.43, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Number of participants with ≥ 50% median reduction in tonic‐clonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.21, 3.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Number of participants with &gt; 25% to &lt; 50% median reduction in tonic‐clonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.33, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Number of participants with 0 to ≤ 25% median reduction or an increase in the number of tonic‐clonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.49, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.13, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lamotrigine + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Rufinamide + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Number of participants with ≥ 50% reduction in all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.31, 6.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Number of participants with ≥ 75 % reduction in tonic‐atonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.71 [1.46, 78.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Number of participants with ≥ 50% reduction in tonic‐atonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.52, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Number of participants with ≥ 25% reduction in tonic‐atonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.93, 3.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Number of participants 'unchanged' (&lt; 25% reduction in tonic‐atonic seizures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.59, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Number of participants with increased tonic‐atonic seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Number of participants with improvement in seizure severity rating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.13, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.86, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Number of participants with adverse events suspected to be treatment‐related <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.90, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Number of participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.13, 5.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.14 [0.49, 34.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Rufinamide + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Rufinamide + ASMs versus other ASM + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Number of participants with treatment‐emergent adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.79, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Number of participants with severe treatment‐emergent adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.20, 4.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Number of participants with serious treatment‐emergent adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.42, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Number of participants with treatment‐emergent adverse events leading to study‐drug dose adjustment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.91 [0.61, 57.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Interruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Number of participants with treatment‐emergent adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.10, 9.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.39 [0.02, 1077.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Child Behaviour Checklist Questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐10.30, 15.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Rufinamide + ASMs versus other ASM + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003277-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topiramate + ASMs versus placebo + ASMs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Number of participants with ≥75% reduction in all seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.22 [0.60, 112.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Number of participants free from major seizures (drop attacks and tonic‐clonic seizures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [1.46, 11.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Number of participants with ≥ 75% reduction in major seizures (drop attacks and tonic‐clonic seizures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.35 [0.97, 19.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Number of participants with ≥ 50% reduction in major seizures (drop attacks and tonic‐clonic seizures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [1.46, 11.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Number of participants free from drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.06 [0.05, 1398.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Number of participants with ≥ 75% reduction in drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.80, 10.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Number of participants with ≥ 50% reduction in drop attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.87, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Number of participants free from drop attacks during the maintenance phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.38, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.9 Number of participants with severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.86, 6.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.10 Number of participants with adverse events leading to dose reduction or temporary discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.90, 10.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.11 Number of participants with adverse events leading to study discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topiramate + ASMs versus placebo + ASMs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003277.pub4/references#CD003277-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003277.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003277-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003277-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003277-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003277-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD003277-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003277-note-0011">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003277-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003277\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003277\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003277\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003277\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003277\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003277.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003277.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003277.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003277.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003277.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715785612"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003277.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715785616"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003277.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8f93bca4f55f',t:'MTc0MDcxNTc4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 